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ABSTRACT
Mechanism of action of NSC3852, a breast cancer differentiation agent.

Anna Martirosyan
The development of tumor cell differentiation agents is new initiative in cancer treatment
research. The goal of this project was to identify breast cancer differentiation agents by
screening quinoline ring-containing compounds obtained form National Cancer Institute
Compound Library. Of six differentiation-inducing quinolines NSC3852 was chosen as a
“lead” compound. Our results demonstrate that NSC3852 is an inhibitor of HDAC
activity in HeLa and MCF-7 cells nuclear extracts. NSC3852 caused superoxide
generation in MCF-7 cells in a NADPH oxidase-dependent fashion, and NSC3852induced oxidative stress led to the shift in a redox potential of the cells to a more oxidized
state. This change in redox status of the cells was accompanied by the accumulation of
hypophosphorylated pRb, downregulation of E2F-1 and Myc transcription factor protein
levels, and cell differentiation. Superoxide formation in response to NSC3852 exposure
caused DNA damage and subsequently apoptosis. MCF-7 cells growth was inhibited. NAcetyl-L-cysteine (glutathione precursor) pretreated MCF-7 cells were protected against
DNA damage, apoptosis, and Rb/E2F/Myc modulation induced by NSC3852.
Inhibition of cell growth and induction of cell differentiation in MCF-7 by NSC3852 was
partially blocked by NAC. This data suggest that mechanisms in addition to oxidative
stress are involved in cell differentiation and growth inhibition by NSC3852 in MCF-7
cells.
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I. INTRODUCTION

1. Breast cancer and current methods of therapy
Cancer of the breast is the most common form of cancer that affects women.
About one in eight women in the United States will develop breast cancer during her
lifetime. Excluding cancer of the skin, breast cancer is the next common cancer among
women. It accounts for nearly one of every three cancers diagnosed in US women. Men
are generally at low risk of developing breast cancer. In 2003, 39,800 women were
expected to die from this disease (American Cancer Society, Surveillance Research,
2003). Only lung cancer accounts for more cancer deaths in women (Jemal A. et al.,
2003). Time since diagnosis, age at diagnosis, stage at diagnosis, race/ethnicity and
socioeconomic factors are the factors that influence breast cancer survival. Factors that
increase the relative risk for breast cancer in women are: age, certain inherited genetic
mutations for breast cancer, two or more first degree relatives with breast cancer
diagnosed at an early age, high – dose radiation to chest, atypical hyperplasia, late age at
full - term pregnancy, early menarche, late menopause, oral contraceptive use, long-term
use of hormone – replacement therapy, and obesity (Hulka B., S. et al., 2001).
Current methods of breast cancer treatment include surgery, radiation therapy,
systemic therapy (biologic therapy, chemotherapy, hormone therapy, and preventive
chemotherapy. Treatment decisions are made after consideration of the optimal treatment
available for the breast cancer patient. A number of parameters, such as tumor size,
involvement of the axillary lymph nodes, presence of metastasis and presence of steroid
receptors are considered.
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There are different surgical options available. Breast-conserving surgery includes
lumpectomy and partial mastectomy. It is followed by radiation therapy. Other types of
surgery include total mastectomy, modified radical mastectomy and radical mastectomy.
Those types of surgery are also followed by adjuvant therapy. Unfortunately, surgery or
radiation therapy involving the axilary nodes can lead to serious swelling of the arm
caused by fluid retention, known as lymphedema. (Fisher B. et al., 2002).
Radiation therapy is the use of high-energy waves (x-rays or gamma rays) or
streams of particles (electrons, protons, neutrons, alpha particles, and beta particles). The
understanding of how radiation works in the body made this, one of the oldest cancer
therapies, a significant part of cancer treatment. Radiation therapy is received by 50-60%
of cancer patients at some time during their cancer treatment. Radiation therapy typically
is used as an adjuvant treatment but can be used before surgery to shrink a large tumor so
that it can be surgically removed. It is also used as a palliative treatment. Radiation
treatment is given in small doses or fractions over several weeks. Cells that are actively
dividing are more radiosensitive, but the disadvantage of the radiation therapy is that it
does not distinguish between cancer cells and cells of normal tissues. And, the damage to
normal cells can result in serious side effects, such as hair loss, lung inflammation, soft
tissue changes, rib fractures, and development of second cancer.
There are two types of radiation therapy. External radiation therapy uses a source
of the radiation outside the body. With internal radiation, the radiation is directed to the
breast region from within the tissue. Radioactive substances sealed in needles, seeds,
wires, or catheters are placed directly into or near the cancer. The advantage of this type
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of radiation therapy is the ability to deliver a high dose of radiation to a small area (Early
breast cancer trialists’ collaborative group, 2000).
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer
cells, either by killing the cells or stopping cells from proliferation. The way the
chemotherapy is given depends on the type and stage of the cancer being treated. If
systemic chemotherapy is used then the drug is taken orally or intravenously, it enters the
blood stream and can reach cancer cells throughout the body. When chemotherapy is
placed directly in the spinal cord, a body cavity such as the abdomen, or an organ, the
drugs mainly affect cancer cells in those areas. Chemotherapy is used as adjuvant therapy
when there is a high risk of disease recurrence or as a neoadjuvant therapy to shrink a
tumor before surgery or radiation therapy.
Chemotherapy may also be used to treat patients with advanced stages of breast
cancer to help control the disease, prolong survival, relieve symptoms, and improve
quality of life. Chemotherapeutic drugs can cause both short- and long term side effects
or complications. Chemotherapy destroys fast growing cells and does not distinguish
between cancer cells and normal, healthy ones. Because cells of skin, nails, hair and
blood divide quickly most common side effects are hair thinning or loss of hair over the
entire body, dry skin, and weak nails. Cells of the digestive tract are affected also; this
explains side effects such as diarrhea, mouth sores, nausea, and vomiting. Blood cells are
affected by chemotherapy. Treatment is suspended if any type of blood cells reaches the
lowest allowed level. As soon as the blood cell production recovers, during a rest period,
treatment can be continued. Some drugs, such as doxorubicin (Adrinomycin) or
epirubicin (Ellence) can cause permanent damage to the heart. More rarely, as a result of
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the chemotherapy itself another cancer develops, such as leukemia. Research has
established that combinations of chemotherapy drugs are more effective than one drug
alone for breast cancer. One of the hurdles in the adjuvant therapy is that the tumor cells
are either inherently resistant or develop resistance to chemotherapy. The use of
combination therapy reduces the chances of the cancer becoming resistant to one drug.
The most common chemotherapy combinations for breast cancer treatment are listed
below: CMF for cyclophosphamide, methotrexate, and 5-fluorouracil; CMFP for
cyclophosphamide,

methotrexate,

5-fluorouracil

and

prednisone;

CMFVP

for

cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone; CAF for
cyclophosphamide, doxorubicin, and 5-fluorouracil; CEF for cyclophosphamide,
epirubicin and 5-fluorouracil, AT for doxorubicin and paclitaxel (Hortobagyi G., N.,
1998).
Estrogen is one of the major promoters of cell growth in hormone dependent
breast cancer. The goal of hormone therapy is to deprive the cancer tissue of estrogen,
resulting in inhibition of cancer cell growth. All breast cancers are now routinely tested
for the estrogen/progesterone receptor status. Hormone therapy has proven effective only
in hormone receptor – positive or unknown status breast cancers. Hormone therapy is not
used with estrogen/progesterone receptor negative breast cancer. Hormone therapy acts
by either blocking estrogen from reaching responsive receptors on cancer cells or
inhibiting the synthesis of estrogen. Hormone treatment include: estrogen receptor
modulators (tamoxifen, raloxifene), used for both pre and postmenopausal women,
considered first-line therapy; aromatase inhibitors (anastrozole, letrozole, exemestane),
which block estrogen synthesis by tissues other than the ovaries and are prescribed only
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to postmenopausal women as first-line therapy instead of tamoxifen, or as second-line
therapy after tamoxifen resistance is developed (Seralini G. et al., 2001); progestins
(megestrol acetate), reduce the effect of estrogen of breast cancer cells and are used as the
third – line therapy, if needed; luteinizing hormone- releasing hormone-like drugs
(goserelin, leuprolide acetate), which reduce estrogen produced by the ovaries, are used
only in premenopausal women, and may be used before, after, in place of, of with
tamoxifen. Tamoxifen is the oldest and the most commonly used antiestrogen drug.
Among the most serious side effects of tamoxifen is increased risk of endometrial cancer.
There have been some reports of liver toxicity, eye problems, slightly increased risk of
stroke or developing cataracts (Early Breast Cancer Trialists’ Collaborative Group,
1998).
Biological therapy also is known as biological response modifier therapy. A good
example of biological therapy is trastuzumab (Herceptin). It is a monoclonal antibody
that binds to the HER-2/neu receptors on the surface of some breast cancers. HER-2/neu
is a normally occurring gene. However, in cancer cells this gene is often mutated and
becomes abnormal. When the HER-2/neu protein binds to the receptor on the surface of
tumor cell, it generates a signal that causes the cell to divide. Overexpression of HER2/neu has been shown to play an important role in the malignant transformation and
aggressiveness of breast cancer. Herceptin binds to the HER-2/neu receptor, making it
impossible for HER-2/neu protein to bind, thus inhibiting tumor from growth. It can be
used alone or in combination with chemotherapy drugs, such as Taxoter (taxol),
Adriamycin (doxorubicin), and cyclophosphamide. Herceptin is well tolerated, but it can
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cause nausea and headache. A serious side effect of Herceptin is heart toxicity (Cobleigh
M., A., 1999).
Surgery, radiation, chemotherapy and hormone therapy can now cure some cases
of cancer. But future methods should be more effective. Therapies that are now available
for internal tumors often give rise to harmful side effects that can compromise the
benefits of treatment. Existing therapies for such internal cancers can also fail in many
cases. Although some advances in the treatment of cancer have been made, the modern
understanding of the genetic basis of cancer is providing the means to find more specific
and less toxic treatments for cancer. The ideal anticancer treatment should be limited to
cancer cells and should cause very few, if any, side effects.
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2. Drug discovery and high – throughput screen
Recent advances in technology, expanded knowledge of the molecular bases of
tumorogenesis and metastasis, and the development of diversity of compounds that can
be tested for activity against known targets lead to the development of increasingly rapid,
selective and reliable high – throughput screening assays, which are applied in the early
phases of drug discovery. These assays allow screening of a very large number of
compounds in an automated fashion. Most high – throughput screening assays can be
grouped into cell – free (biochemical) or cell based (ex – vivo) assays. Cell based assays
are becoming more widely used format in high – throughput screening, because
compounds initially identified in a biochemical assay sometimes fail later in the
discovery process as drug candidates. In some cases they are not able to penetrate the
cell; in other cases they do not interact with the target effectively in the cell. Commonly
used cell based assays include enzyme – reporter assay and cell activity assays with
fluorescent, luminescent or colorimetric readouts. Automated assays allow rapid
screening of large compound libraries to identify compounds that show the desired effect,
or so cold “hits” (Hertzberg R., P. et al., 2000). A good example of high – throughput
screening of large compound library is the In Vitro Cell Line Screening Project. This
project required approximately five years (1985 - 1990) to develop. The project is
designed to screen up to 20,000 compounds per year for potential anticancer activity, and
the operation of this screen utilizes 60 different human tumor cell lines (representing
leukemia, melanoma and cancers of the lung, colon, brain, ovary, breast, prostate, and
kidney). The aim of the project is the development of the library of compounds, showing
selective growth inhibition or cell killing properties in particular tumor cell lines,
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available for further evaluation (NCI, DTP human tumor cell line screen,
http://dtp.nci.nih.gov/branches/btb/ivclsp.html). Hits are then further screened to select
more specific and potent compounds called “leads”. The next step in the drug discovery
process is further testing of the leads to determine targets upon which they act (if not
known) in cells with subsequent in vivo assays (animal models) in order to select
compounds that may become drug candidates for clinic (Johnston P., A. et al., 2002).
In this study we preformed high-throughput screening of quinoline ringcontaining compounds obtained from National Cancer Institute Compound Library to
identify “lead” compound, and further investigate its mechanisms of action.
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3. Cell growth control
3.1. Cell cycle (general overview)
Cell division is a process that is required throughout the life of all eukaryotic
cells. The replicative cycle of the cells, which ensures that there is complete and accurate
replication of the cell before the division is known as the cell cycle (Figure1). It is a
highly organized and complex process that requires a carefully timed sequence of events
including cycle alterations in gene expression and protein phosphorylation. The length of
the cell cycle can vary considerably. There are two principal stages of the cell cycle:
interphase and mitosis. The period between cell divisions when the cell possesses an
intact nuclear membrane, with chromatin dispersed throughout the nucleus is called
interphase. Stage of the division itself is called mitosis. Interphase is subdivided into G1,
S and G2 phases. Cell division (cytokinesis) occurs during mitosis (M) phase. G1 (G for
gap) phase follows mitosis. During this phase the cellular genome is in the diploid state.
This is followed by S phase (synthesis), during which DNA is replicate, and finally by G2
during which essential proteins for M phase are synthesized. A fifth phase has also been
identified and is known as G0. It occurs when a viable cell is not involved in the active
cell cycle. Cells enter such quiescent phase under the certain conditions such as starvation
or differentiation. Some non-dividing cells, for example neurons or skeletal muscle
fibers, are said to be in G0 phase and are not able to re – enter the cell cycle. Other cells,
such as hepatocytes, fibroblasts and lymphocytes can be stimulated into the cell cycle by
external factors (mitogens). G0 cells perform tissue – specific functions, but unlike
terminally differentiated cells, G0 cells retain the ability to enter the proliferating cell
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Figure 1. The Cell Cycle. Cyclins and cyclin-dependent kinases during the cell cycle.
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cycle, responding to extracellular factors. The decision for the G0 cell to enter the cell
cycle or for the cycling cell to exit into G0 is made shortly before S in late G1 period.
The phases of cell cycle have no definite start and finish point, but each one is a
stage at which one function is coming to an end and another is beginning. The cell cycle
is controlled by three families of cell cycle regulators: cyclins, cyclin dependent kinases
(CDKs), and cyclin – dependent kinase inhibitors. The concentration of cyclins varies
during the course of cell cycle. Once the concentration of cyclin has reached a critical
level (as a response to mitogenic stimuli) it binds to corresponding CDK and activates it.
Some CDKs are activated by more than one cyclin. Currently, 14 cyclins and 8 CDKs
have been identified, although the function of all of them has not been resolved (Gillett
C., E. et al., 1998). There are two important decisions made during cell cycle: cell
decision to enter from G1 into S phase, which is made late in G1 (G1 checkpoint), and cell
decision to enter mitosis (G2 checkpoint). Cyclins and CDKs play key role in control of
cell cycle checkpoints. G1 checkpoint is controlled by retinoblastoma nuclear
phosphoprotein (pRb). pRb is controlled by changes in its phosphorylation state (Figure
2). During G0 and early G1 phases pRb acts as an inhibitor of cell cycle and is present in
its hypophosphorylated form. In that form pRb is bound to E2F transcription factor and
keeps it transcriptioanlly inactive. At G1 checkpoint however, pRb becomes
phosphorylated by complexes of cyclin D with CDK4/6, and of cyclin E with Cdk2.
Upon phosphorylation a transcriptionally active E2F is released, it induces several cell
cycle - dependent genes including those for thymidine kinase, dihydrofolate reductase,
DNA polymerase α, the protooncogenes c-myc and N-myc, cdc2, the genes for cycline E
and A, and E2F gene itself. These events ensure G1 to S progression. Detailed
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Figure 2. Schematic representation of pRb phosphorylation and E2F
release during G0-S transition.
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description of G1 to S progression is given later in introduction. G2 checkpoint is
controlled by M phase promoting factor (MPF), which consists of CDK1 and its
activating mitotic cyclins, cyclins A and B. Cyclin A-CDK1 controls the completion of S
phase and the preparation for mitosis. The B cyclins take over from cyclin A as active
partner of CDK1 during mitosis, and cyclin B-CDK1 controls mainly the completion of
mitosis. Mitotic division starts only when CDK1 has been phosphorylated at threonine 14
and tyrosine 15 by WEE1 (Cdc2-specific tyrosine kinase), at threonine 161 by CAK, and
dephosphorylated at threonine 14 and tyrosine 15 by CDC25 (Lohka, M. J., et al., 1988).
The activation of CDK1 leads to the phosphorylation of structural proteins in nucleus,
such as nucleolin, nuclear lamins, and vimentin, and cell proceeds to the subsequent
stages of mitotic and cellular division. As it was mentioned above, activation of CDK by
cyclin plays an important role in cell cycle progression. But CDKs are also regulated by
CKIs. These inhibitors can be upregulated and, thus block activation of CDK by cyclin
when required. There are two families of CKIs: Ink4 and Cip/Kip. The Cip/Kip family
consists of p21, p27 and p57. These inhibitors have wide ranging roles and inhibit a
number of different CDKs. The Ink4 family consists of p15, p16, p18 and p19. Members
of this family inhibit the action of CDK4, and p19 also was shown to inactivate MDM2
(p53 regulatory protein), allowing increase in p53 stability and subsequent cell cycle
arrest (Pomerantz J., et al., 1998).
There are two distinct forms of eukaryotic cell death: necrosis and apoptosis.
Necrotic cell death is caused by gross cell injury, and results in the death of groups of
cells within the tissue. In contrast, when a cell reaches G1 checkpoint, it can be directed
to go into S phase or, if the cell is likely to be damaged, it can be sent into programmed
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cell death, known as apoptosis. It can result in the death of an individual cell. Apoptosis
is the most common form of eukaryotic cell death. Inappropriate regulation of apoptosis
plays an important role in pathological conditions such as cancer (Gerard I. Evan and
Karen H. Vousden, 2001). Apoptosis is regulated in the cell by cysteine proteases known
as caspases, and it is a process characterized by specific morphologic and biochemical
changes. There are two main pathways to apoptotic cell death. One involves so called
death receptors, such as TNF or the FAS. The second pathway depends on participation
of mitochondria, and is regulated by proapoptotic and antiapoptotic members of Bcl-2
family. Both pathways have the same end result: activation of caspase and subsequent
cleavage of specific cellular substrates (Katja C. Zimmermann and Douglas R. Green,
2001). During apoptosis the endogenous endonuclease cleaves double stranded DNA at
the

most

accessible

internucleosomal

linker

regions,

generating

mono-

and

oligonucleosomes. Due to the fact that DNA degradation occurs several hours before
plasma membrane breakdown, there is the specific stage of apoptosis that is characterized
by the enrichment of mono- and –oligonucleasomes in the cytoplasm of the apoptotic
cells (Terui, Y. et al, 1995).
There has been considerable progress in identifying the molecules that drive the
cell cycle, and accumulating evidence indicates that derangements in the cell cycle
machinery contributes to the uncontrolled cell growth: the hallmark of cancer.
Most experiments in this study were done using the MCF-7 breast cancer cell line.
A short description of the duration of cell cycle phases in MCF-7 cells is given below
(Wang S. et al., 1998):
Doubling time - 52 hours
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Duration of G1 - 32 hours
Duration of S - 15 hours
Duration of G2 / M -5 hours

3.2. Cell cycle dysregulation and differentiation therapy
Alteration in the components of the cell cycle machinery and checkpoint
regulation pathways occur in most human tumors. It is found that in tumor cells genes
that restrain cell division (tumor suppressor genes) are defective, while those that
promote division (oncogenes) become more active. For example, loss of pRb tumor
suppressor function leads to abnormal proliferation as a result of the deregulation of the
E2F transcription factor (Nevins, J. R., 1998). In humans, inactivation of pRb is most
commonly observed in retinoblastomas, osteosarcomas, carcinoid tumors, and small-cell
lung cancer (Sherr C. J., 1996). Increased levels of cyclin D and cyclin E, amplification
of the gene that encode CDK4 and CDK6 and deletion of p16 occur in a variety of human
tumors, including breast and lung cancer, retinoblastoma and osteosarcoma (Zheng L. et
al., 2001). The most frequently observed genetic lesion in human tumors is mutation in
p53 tumor suppressor gene. p53 function might be disrupted also by alteration in cellular
proteins, which modulate the expression, localization and activity of p53 protein
(Momand J. et al., 1998). Regulation of c-myc oncogene expression is also critical for
controlling cell proliferation. Alterations in c-myc gene expression due to chromosomal
transformation, gene amplification, or point mutation in c-myc coding sequence have
been demonstrated in Burkitt’s lymphoma, myeloid and plasma cell leukemia, breast
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carcinoma, cervical carcinoma, small cell lung carcinoma, colon carcinoma,
osteosarcoma, and glioblastoma (DePinho R. et al, 1991).
The detailed information about how cell cycle events are dysregulated in cancer
gives us new opportunities to develop novel cancer therapy agents. The goal of therapy is
to selectively kill cancer cells, and as cancer cells have a defective checkpoint
mechanism, they may be more susceptible to chemotherapy than the normal cells.
One of the new approaches to cancer eradication is differentiation therapy. In
humans, this technique was not used until it was shown that all-trans-retinoic acid could
restore normal differentiation of the immature white blood cells of acute promyelocytic
leukemia (Tallman M. S. et al., 1997). Differentiation therapy states that genes required
for normal growth and differentiation are not necessarily lost during malignant
transformation, but the regulation of these genes is often lost. Thus, even though there is
a genetic alteration that is pushing cells through the cell cycle, perhaps there are other
switches that can be used to stop this uncontrolled cell proliferation. In this type of
therapy, the cells are treated with agents that would cause them to mature, thereby
causing them to become less proliferative. Overall, differentiation therapy does not fix
the genetic defect, but it modulates gene expression to control the cell cycle progression.
Well studied targets for tumor differentiation agents are histone deacetylases
(HDACs). HDACs are responsible for the hydrolytic removal of acetyl groups from
specific histone lysine residues, acetylation of which is catalyzed by histone
acetyltransferases (M. Grunstein, 1997). Common profile of responses to the catalytic
HDAC inhibitors includes histone hyperacetylation, elevated expression of the cyclin-
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dependent kinase inhibitor p21, cell cycle arrest and apoptosis (Vigushin D. M. et al.,
2001).
Our knowledge of cell-cycle checkpoints offers hope for developing novel
mechanism-based approaches to cancer treatment that will specifically target aberrant
proliferation.
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4. pRb/ E2F/ Myc pathway
4.1. Retinoblastoma family
4.1.1. Structural characteristics
The retinoblastoma gene (Rb) was the first tumor suppressor gene to be identified and it
became the prototype for the study of human suppressor genes. Its absence or mutation is
involved in the development of various types of human tumors (Nevins, J. R., 1998). The
ability of pRb (Rb-gene product) to interact with other cellular proteins that affect
transcription assures its role in regulating cell cycle, apoptosis and differentiation. Human
pRb contains 928 amino acids (Figure 3). It is nuclear phosphoprotein with a half-life
more than 8 hours. pRb belongs to the retinoblastoma gene family along with two other
members: p130 and p107 which are structurally similar to pRb (Mayol X. et al., 1993).
All three family members contain a so-called pocket domain, which is critical to the
tumor-suppressor function of retinoblastoma protein and is the region of tumorigenic
mutations. The pocket domain is highly conserved region, which is responsible for giving
a particular conformation to the proteins, thus it sustains the proteins functional activity
(Xiao B. et al., 2003). In this region p107 and p130 are more closely related to each other,
than they are to pRb. The pocket domain is subdivided into two conserved subdomains
termed A and B and separating them is a spacer region. p107 and p130 have specific
motif in spacer region that is not presented in pRb, which enables them to form strong
binding site for cyclin A/CDK2 and cyclin E/CDK 2 (Li Y. et al., 1993; Faha B. et al.,
1992). p107 and p130 also share a homologous sequence near the aminoterminus that is
absent in pRb. The amino-terminal region of retinoblastoma proteins is still under
investigation. It contains CDK phosphorylation sites, which may regulate Rb’s activity
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Figure 3. Putative regulatory features of retinoblastoma proteins. Red
dots represent phosphorylation sites.

19

during the cell cycle. The number of endogenous pRb-binding proteins contains LXCXE
motifs. Specific residues in the pocket region of pRb interact with proteins that carry an
LXCXE peptide sequence. Proteins that contain LXCXE-like sequence include chromatin
remodeling proteins, such as HDAC-1 and HDAC-2 (Magnaghi J.L. et al., 1998). The
LXCXE binding site is not the only binding site in the pocket region. The E2F
transcriptional family and several oncoproteins, such as E1A and E7 lack LXCXE
peptide sequence, but these proteins also bind pRb at a site that involves pocket and
adjacent C-terminus (Lee I.O. et al., 1998). The analysis of pRb structure showed that it
contains a number of phosphorylation sites, but the exact number of the residues that can
be phosphorylated during the G1 phase is not yet clear.

4.1.2. Functional characteristics
The pocket proteins are differently expressed throughout the cell cycle. pRb is
expressed steadily throughout the cell cycle, p130 is increased in arrested cells, whereas
p107 expression is high during the S phase of the cell cycle (Tonini T. et al., 2002). Each
of the Rb family proteins binds to and modulates the activity of the E2F family of
transcription factors (Figure 4). p130 is associated with E2F-4 and E2F5. p130 and E2F-4
is the most abundant E2F complex found in resting or quiescent cells and is thought to be
a repressor complex. pRb forms complexes with E2F-1, E2F-2, E2F-3 and E2F-4. p107 is
found to form complex with E2F-4 and E2F-5. Retinoblastoma family members
demonstrate cell growth suppressive properties between the G1 and S phases of the cell
cycle. This negative control of the cell cycle is mostly due to the inactivation of
transcription factors. All three proteins are regulated by cyclinc events of phosphorylation
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and dephosphorylation. pRb is thought to function as the guardian of the G1/ S phase
transition. pRb arrests cells in G1 by binding to the members of E2F/DP family of
transcription factors and inhibiting their activity. Phosphorylation of pRb is in the cell
cycle dependent manner, and it leads to the release of free, transcriptionally active E2F.
Subsequent activation of E2F-responsive genes during late G1 seems to be enough to
commit cells to start DNA replication. pRb phosphorylation is mediated by cell cycledependent kinase complexes Cdk4/Cdk6-cyclin D and Cdk2-cyclin E. Interestingly,
phosphorylation of specific pRb phosphoacceptor sites may modulate biochemical
activities of the protein. For example, phosphorylation of Ser608, Ser621 disrupts the
binding of pRb to E2F, whereas phosphorylation of Thr821 and Thr826 affects the
binding of pRb to LXCXE proteins. Present recent studies also suggest that certain pRb
phosphoacceptor sites are preferentially phosphorylated by specific cyclin/CDK
complexes. For example, Ser780, Ser807, Ser811 and Ser795 are phosphorylated by
cyclin D/ CDK4, whereas Thr821 is preferentially phosphorylated by cyclin E/ CDK2
complexes (Knudsen E. S. et al., 1996; Knudsen E. S et al., 1997; Zarkowska T. et al.,
1997). It is important to mention, that the phosphorylation state of a given protein
depends on the ratio of protein kinase and phosphatase activities. This ratio is crucial for
proper cell cycle regulation, because at times, dephosphorylation of CDK substrates may
be necessary to ensure an orderly cell cycle. There are four prototypes of mammalian
Ser/Thr-specific protein phosphatases: PP1, PP2A, PP2B and PP2C. PP1 was identified
as the phosphatase responsible for the dephosphorylation and thus, activation of pRb
(Durfee T. et al., 1993). PP2A specifically associates with p107, leading to the
subsequent dephosphorylation of p107 (Voorhoeve P. M. et al., 1999).

Another
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mechanism of pRb mediated repression of growth is associated with HDACs. pRb can
bind at least two members of HDAC family, HDAC1 and HDAC2. HDAC-1
preferentially binds to the active, hypophosphorylated form of pRb. Furthermore, E2F-1
binds this complex, creating a trimeric complex. Thus, this complex can be recruited to
the E2F-1 responsive S-phase-specific promoters. HDAC then deacetylates the
nucleosomes surrounding the promoter, induces changes in chromatin conformation, and
prevents transcription factors access to their binding sites. Prior to G1 / S transition, pRb
phosphorylation leads to the dissociation of E2F/pRb/HDAC repressor complex (Brehm
A. et al., 1999).
pRb is not only a growth suppressor gene, it also exhibit anti-apoptotic properties.
Loss of pRb function results in release of free E2F, which in its turn is targeting p19 (the
alternate reading frame encoded by the p16INK4a locus). Increase in p19, which function
is inhibition of MDM2-mediated turnover of p53, leads to an increase in p53 and
apoptosis (Morgenbesser S. D. et al., 1994). The role of p107 and p130 in apoptosis is not
defined yet.
The retinoblastoma family is involved in cellular differentiation. Several studies
demonstrate an interaction between the retinoblastoma family protein and differentiationspecific transcription factors, such as MyoD and HBP1 (Yee A. S. et al., 1998). All three
retinoblastoma proteins are highly expressed in some terminal differentiation cells. The
ability of pRb to induce cellular differentiation is due to the fact that pRb forms
complexes, and subsequently modulates various specific transcription factors.
In the next section the best-studied binding partner of retinoblastoma proteins –
the E2F family of transcription factors are discussed.
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4.2. The E2F transcription factors
E2F transcription factor plays a key role in cell proliferation, as it links the
activities of the cell cycle machinery with the transcriptional regulation of genes required
for S-phase entry, such as CDC6, as well as genes regulating cell cycle, such as cdc25A,
cyclin E, E2F-1, pRb, B-myb and c-myc. E2F DNA-binding sites (TTTC/GG/CCGC/G)
are found in the promoters of those genes (Dyson N. et al., 1998). In addition to
regulating S-phase entry, E2F factors are involved in cell growth inhibition,
differentiation, apoptosis and oncogenic transformation.

4.2.1. The E2F family
There are two distinct groups of genes that have been identified as components of
E2F transcriptional activity: E2Fs (E2F1-E2F6) and the DPs (DP1 and DP2). Protein
products from these two groups heterodimerize and give rise to all possible combinations
of E2F-DP complex. It is established that E2F binds DNA in a DP-dependent manner.
Heterodimerization not only improves E2F ability to bind DNA, it also increases
pRb/E2F complex stability (Helin K. et al., 1993). DNA-binding domain is found in the
amino terminus, and represents the area of greatest homology between E2Fs (E2F1E2F5). The DP dimmerization domain is adjacent to the DNA-binding domain. The
carboxy termini of E2F1- E2F5 contain the defined transcriptional activation domain.
There is a third conserved regions between the different E2Fs, which lays between DP
dimerization and transcriptional activation domains, named Marked box, but its function
is unknown. E2Fs are divided into three subgroups. E2F1, E2F2 and E2F3 are known as
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transcriptional activators with maximal accumulation at the G1/S boundary. These E2Fs
are highly homologous in the DNA binding domain, DP dimerization and pRb biding
domains and are similar in the ability to preferentially interact with pRb but not with
p130 or p107. The E2F binding to pRb-family is mediated by a short, highly conserved
domain near the carboxyl terminus of the E2F proteins. This binding domain overlaps
with the transactivation domain. The amino termini of E2F1-E2F3 contains an additional
region of homology not found in E2F4 or E2F5. This region binds cyclin A protein (Krek
W. et al., 1994). Overexpression of any member of this subgroup is sufficient to induce
resting cells to re-enter the cell cycle. The second group consists of E2F4 and E2F5.
Members of this group bind all three Rb family members but appear to be primarily
repressors of E2F-responsive genes. E2F6 is the only member of the third subgroup. It
also acts as a transcriptional repressor but through pocket-protein-independent
mechanism, because it lacks carboxy-terminal sequences. (Trimarchi J. M. et al., 1998).
The expression of the various E2F family members differs during the cell cycle. The
E2F1 and E2F2 levels are usually increased at the G1/S-phase boundary. E2F3 and E2F5
expression levels rise in early-to-mid G1 and do not increase after cell enters S phase
(Slansky J. E. et al., 1996). E2F-4 expression is slightly increased in mid G1, but it is
constitutively expressed during all cell cycle phases, even in growth arrested cells (Sardet
C. M. et al., 1995).

4.2.2. Regulation of E2F factors by the Rb family of pocket proteins
The activity of E2F factors are regulated through the association with members of
Rb family. Pocket protein binding inhibit the transcriptional activity of E2F factors by
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masking the transcriptional activation domain, and in some cases, converts E2F factors to
repressors of transcription. Several studies demonstrated a correlation between the ability
of Rb to arrest cells in the G1 phase and to bind E2F (Qian Y. C. et al.,1992). E2F family
members interact with specific pocket proteins in vivo. E2F-1, E2F-2 and E2F-3
associate exclusively with pRb. E2F-4 associates with all three of the pocket proteins.
E2F-5 associates only with p130 protein. The presence of E2F-pocket complexes varies
in the cell cycle-regulate manner. E2F binding can be inhibited by the phosphorylation of
pRb, because hypophosphorylated pRb has low affinity for E2F. Release of free E2F
leads to the activation of E2F-dependent transcription of several S-phase entry genes,
such as c-myc, cdc25A, cyclin E. Association of E2F with Rb is not the only event that
contributes to the inactivation of E2F in S phase. Free E2F-1 and E2F-4 are degraded by
the ubiquitin-proteosome pathway (Hateboer et al, 1996).
It has been found that association of pocket proteins with E2F factors can also
result in the formation of transcriptional repressor complexes. For example in B-myb and
RB1 E2F DNA-binding site functions as negative regulatory element (Johnson D. G. et
al., 1994). Repression by pocket proteins involves the association of other proteins in
addition to E2F factors, such as BRG1 and HDAC1. Those proteins are involved in
remodeling of chromatin structure (Brehm A. et al., 1998; Dunaief J. L. et al., 1994).
What factors play role in determining whether a given E2F site will function as a positive
or negative regulatory element is at present unclear.
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4.2.3. Control of apoptosis by E2F-1
Overexpression of E2F-1 can induce a cell to undergo programmed cell death or
apoptosis (Wu X. et al., 1994). The p53 protein is a key player in cellular decision to
either arrest the cell cycle, or to commit to cell death. In p53-null mouse embryo
fibroblasts, E2F-1 is much less efficient at inducing apoptosis. E2F-1 induces the
expression of p19, which negatively regulates Mdm2, which in its turn negatively
regulates p53 (DeGregori J. et al., 1997). This pathway establishes direct connection
between E2F-1, p53 accumulation and apoptosis. E2F-1 can also induce apoptosis in a
p53 independent manner, by inducing specific expression of Apaf1. Apaf1 in
combination with cytochrome C and the caspase 9 protease forms the so-called
apoptosome, which activates the downstream caspase proteases: the final effectors of cell
death (Moroni M. C. et al., 2001).
E2F is one of the regulators of c-myc gene transcription. The function of Myc, cmyc gene product, as a downstream effector of E2F is discussed in next section.

4.3.The c-myc transcription factor
4.3.1. c-myc transcription factor: regulation of the cell cycle, cellular
differentiation and apoptosis
The myc family of proto-Oncogenes includes three genes: c-myc, N-myc and Lmyc, which encode related proteins. It is well recognized that altered c-myc expression is
involved in a wide variety of human tumors including breast, colon, and cervical
carcinomas, osteosarcomas, glioblastomas and myeloid leukemia (Marcu K., et al., 1992;
Spencer C., et al., 1991). Myc is a transcription factor of the Basic- helix – loop – helix –
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leucine zipper (bHLH-Zip) family. It dimerizes with another bHLH-Zip protein, Max, to
bind the specific DNA sequence CACGTG (the E-box). Binding of Myc-Max
heterodimers to the E-box sequences leads to the transactivation of Myc target genes.
Max also forms heterodimers with the bHLH-Zip proteins Mad or MXI-1. These
alternative dimers lack transactivation function, and may block the biological effect of
Myc, by competing for the same binding site (Ayer D. E. et al., 1993). A number of Myc
target genes were identified, such as genes that encode cdk-4 and cdc25A phosphatase
proteins (Hermeking H. et al., 2000; Galaktinov K. et al., 1996).
Like E2F, the Myc protein has also been shown to play a critical role in the
control of cell proliferation. In quiescent cells, c-myc expression is almost undetectable,
but as a cell enters G1 there is a transient burst in Myc protein expression, which declines
to low steady-state levels in proliferating cells (Kelly K. et al., 1984). Several studies
show that induction of c-myc expression following serum stimulation of quiescent cells is
an important step towered the transition from G0 to G1 phase in nontransformed cells
(Shichiri M. et al., 1993).
In addition to a role of Myc in cell proliferation control, it plays an important role
in cellular differentiation. Downregulation of Myc expression is essential for terminal
differentiation and withdrawal from the cell cycle (Griep A. E. et al., 1988).
Similar to the Rb/E2F pathway, Myc expression couples cellular proliferation
with the induction of apoptosis under the conditions where survival growth factors are
limited. Myc-induced apoptosis involves the induction of p19, inhibition of MDM2, and
elevated p53 expression (Zindy F. et al., 1998).

28

4.3.2. Connection between Myc and Rb/E2F pathway
Myc and E2F transcription factors share a number of functional properties, such
as the ability to induce quiescent cells to enter the cell cycle and progress into S phase
and to control the cell fate by activating p53 dependent apoptosis. Two E2F binding sites
are located on the c-myc promoter and it has been recently shown that E2F activity is
required for the ability of Myc to stimulate quiescent fibroblasts to progress into S phase
(Leone G. et al., 2001). Furthermore, Myc overexpression has also been reported to
induce E2F DNA binding activity (Jansen-Durr P et al., 1993), and directly contribute to
the activation of E2F-1, E2F-2 and E2F-3 genes (Leone G. et al., 1997).
Most likely, Myc-mediated induction of CyclineD/Cdk4 or Cyclin E/cdk2 leads to
the phosphorylation and inactivation of Rb family members, with subsequent release of
free E2F transcription factor.

5. Cellular redox regulation
5.1. ROS formation and its role in signaling pathways
Formation of reactive oxygen species (ROS) is a consequence of aerobic
metabolism, when cells are constantly engaged in redox reactions where electrons are
exchanged between O2, N2 and cellular components. When ROS levels exceed the
antioxidant capacity of a cell, a condition known as oxidative stress occurs. Excessive
ROS can lead to the damage of cellular components, such as lipids, proteins, and DNA (
Figure5). Thus, it is generally believed that accumulation of ROS, which include
hydrogen peroxide (H2O2), supreoxide anion, and hydroxyl radicals leads to initiation of
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numerous pathologies, including tissue ischemia and reperfusion, cancer, diabetic
vasculopathy, atherosclerosis, Alzheimer’s disease, and pulmonary fibrosis (Finkel T. et
al., 2000; Mates J., M. et al., 1999; Davies K., J. et al., 2000). To defend against
oxidative damage induced by ROS, a series of enzymatic (superoxide dismutase, catalase,
glutathione peroxidase) and non–enzymatic (glutathione, α-tocopherole, ascorbate)
antioxidant defenses have evolved that neutralize ROS. However, formation of ROS is
not always associated with cell damage. It is now clear that ROS have a cell signaling
role in numerous of biological systems. ROS are considered as a potential signaling
molecules because they are: 1) produced by the cells upon certain stimulation; 2) have an
action in the cell which produces it or a nearby cell; and 3) is removed in order to turn
off, or reverse the signal (Hancock J., T. et al., 2001).
Several enzymes are potentially able to generate ROS: nicotinamide adenine
dinucleotide (NADH) (or NADPH) oxidase, xanthine oxidoreductase, organelles
containing electron transport system, such as mitochondria, and preoxidases. NADPH
oxidase complex is now recognized as a primary source of ROS (Figure 5). NADPH
oxidase is a multisubunit complex that contains the two subunits of membrane-bound
cytochrome b-558 (p22-phox and gp91-phox), and three cytosolic proteins (p40-phox,
p47-phox, and p67-phox). Two small G-proteins are also associated with NADPH
oxidase: Rac and Rap. (Honckock J. T. et al., 2001). Rac mediates the association of the
p47-phos and p67-phox on the cytosolic side of the plasma membrane whereas Rap is
involved in the regulation of association with the cytochrome b component (Gabig T. G.
et all, 1995). NADPH oxidase catalyses one-electron reduction of molecular oxygen, with
electron supplied by NADPH. Formed superoxide is further reduced to hydrogen
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peroxide. Superoxide may also react with nitric oxide to form peroxynitrite. Therefore,
under the physiological conditions, once superoxide is formed, a cascade of ROS
production is likely. Certain ROS species (hydroxyl radical, peroxynitrite) cause direct
cellular damage. Other oxygen species (superoxide anion, hydrogen peroxide) play an
important role in regulating the cellular redox potential.

5.2. Cellular redox potential
Redox potential (Ec) is a physical property that determines the ease with which
electrons transfer among all intracellular components. Glutathione is the primary buffer
of intracellular redox status. A good estimate of Ec can be calculated from the ratio of
Glutathione (GSH)/Glutathione disulfide (GSSG). The Nernst equation gives the redox
potential in terms of GSH and GSSG concentrations (Hoffman A. et al., 2001):
E = E0 + 30 log {[GSSG] / [GSH]2}, where E0 is the standard potential of the
GSH/GSSG couple (-0.24V) (Jones D. P. et al., 2002).
GSH, a tripeptide (γ-glutamylcysteinylglycine) with a free thiol group, is a major
antioxidant in human tissues. Glutathione synthase (GS) is an enzyme that synthesizes
GSH de novo from amino acid precursors. Exogenous precursors for GSH (Nacetylcysteine) reduces Ec by this route. The reaction between GSH and cytoplasmic
oxidants produces GSSG. When mammalian cells are exposed to oxidative stress, the
ratio of GSH/GSSG decreases and redox potential rises (Ec will become less negative).
The GSSG is later recycled to GSH by reduction by NADPH. This reaction is catalyzed
by glutathione reductase (GR). Changes in redox status of the cells affect cellular
proliferation, differentiation and apoptosis.
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5.3. Modulation of the cell cycle and differentiation by cellular redox
potential
Changes in redox potential may lead to changes of intracellular signals (Figure 5)
that mediate cell proliferation, differentiation, apoptosis and mitogens-activated protein
kinase (MAPKs) cascade (Wang S. et al., 1998; Tardif M. et al., 1998). The mechanisms
that couple those cellular events and redox potential of the cells are studied intensively.
Cysteine containing proteins can serve to couple cellular redox status and protein
function, because they can form disulfide bonds (S-S) between two –SH groups of
neighboring cysteine residues, in a sufficiently oxidizing environment. These bonds are
important for stabilizing three dimensional structures of the proteins. When redox
potential of the cell is low, disulfide bonds can break, and the new ones are not formed. It
has been reported by several laboratories that cellular redox potential is involved in
physiological cellular signaling and cell cycle regulation. For example, GSH depleting
agent, diethylmaleate, cause oxidative stressing HeLa cells, which leads to pRb
hypophosphorylation and G1 cell cycle arrest (Esposito F. et al., 2000). Interestingly, the
cell cycle arrest in G1 as a response to the depletion of intracellular GSH, can be reversed
by GSH precursors, such as N-acetylcysteine (Hoffman A. et al., 2001). In light of the
above Hoffman et al proposed a model for redox dependent cell cycle arrest. In this
model mild oxidative stress resulting in decreased GSH concentration prevents pRb
phosphorylation with subsequent G1 arrest. Similar results were obtained by L. Cicchillitti
et

al.

They

demonstrated

that

oxidative

stress

induces

PP2A-dependent

dephosphorylation of the pocket proteins pRb, p107, and p130 (Cicchillitti L. et al, 2003).
There are studies demonstrating the involvement of redox systems in cell proliferation.
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Activation of membrane redox system results in stimulation of growth in cells, whereas
the inhibition of membrane redox activity causes retardation of cell proliferation (Morre
D. J. et al., 1998). Furthermore, several reports have shown that MAPKs are activated by
ROS, which could lead to modulation of gene expression (Tardif M. et al., 1998).

The goal of this study was to investigate mechanism of action of NSC3852
differentiation inducing quinoline identified by screening of quinoline ring-containing
compounds.

34

Research objectives
Previous studies in our laboratory demonstrated that quinidine, a quinoline ring
containing compound, caused mid G1/G0 arrest, inhibited proliferation, negatively
regulated HDAC and stimulated differentiation in MCF-7 breast tumor cells. Extended
studies showed most but not all quinoline antimalarials caused some degree of growth
inhibition and differentiation (Oil Red O assay) in breast cancer cells (Johnson D. N. et
al, 1999).

I.

The first goal of this project was to find a more potent compound to
induce a more differentiated phenotype in breast cancer cells in
vitro.

1.

We hypothesize that the quinoline aromatic ring system contains a property
that promotes differentiation in breast tumor cells. The MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) assay, a method that we used to measure relative viable cells in
control versus treated samples, to assess the growth inhibiting properties of
twenty three quinoline ring compounds. IC50 values of the compounds were
determined. Using MTS IC50 levels of each compound, we found five
quinoline ring – containing compounds induced accumulation of G0 cells and
differentiation (Oil Red O) in MCF-7 cells at MTS IC50 concentrations lower
than the IC50 concentration of quinidine.
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2. We tested whether DNA damage or/and apoptosis contributed to the
growth inhibition induced by quinoline ring – containing compounds. We
identified NSC3852, a compound that caused DNA damage and induced
apoptosis in breast cancer cells.

Based on the data obtained from those experiments we chose NSC3852 as
our lead compound for further investigation.

II. The second goal of the project was to identify mechanism by which
NSC3852 arrests cell growth and induces G0 accumulation.

1.

Hypophosphorylated pRb prevents cycle progression (Nevins J.

R.,1998). We hypothesized that cell cycle arrest caused by NSC3852
results from pRb hypophosphorylation. Our results indicated that
NSC3852 caused accumulation of the hypophosphorylated form of pRb.
We predicted that hypophosphorylation of pRb would cause suppression
of E2F-1 activity as well as downregulation of its downstream product
Myc protein. Our results indicate that NSC3852 downregulated levels of
E2F-1 and suppressed its activity as transcription factor. NSC3852 also
downregulated levels of Myc protein and suppressed its activity as a
transcription factor.
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2.

Elevated redox potential causes the accumulation of pRb protein in

its hypophosphorylated form (A. Hofman et al., 2001). We hypothesized
that redox status contributes to action of NSC3852 on pRb
phosphorylation. This hypothesis predicts N-acetylcysteine (NAC), a GSH
precursor, will reverse the action of NSC3852 pRb phosphorylation. Our
results indicate that NAC reversed accumulation of hypophosphorylated
pRb, and reversed NSC3852 induced decrease in E2F-1 and Myc protein
levels.

3.

NSC3852 induced DNA damage and apoptosis in MCF-7 cells.

We tested the hypothesis that redox activity of NSC3852 resulted in
induction of DNA damage and apoptosis in MCF-7 cells. We predicted
that NAC will reverse the DNA damage and apoptosis induced by
NSC3852 in breast cancer cells. Our results showed that cells pretreated
with NAC were protected form NSC3852 induced DNA damage and
apoptosis.

4.

NSC3852 suppressed growth of MCF-7 cells. We hypothesized

that NAC reverses the effect of NSC3852 on cell growth. Cell growth
experiments showed that NAC only partially reversed the effect of
NSC3852 on cell growth.
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5.

We hypothesized that NAC sensitive hypophosphorylation of pRb

is necessary for the differentiation response induced by NSC3852 in MCF7 cells. Therefore, we tested whether accumulation of G0 cells induced by
NSC3852 is reversed by NAC. Ki67 immunohistochemistry was
performed. Results obtained from those experiments indicate that NAC
only partially reversed the cell cycle arrest induced by NSC3852 in MCF7 cells.
6.

Based on the fact that NSC3852 induced changes involve NAC

responsive redox pathway we hypothesized that NSC3852 mediates ROS
generation in MCF-7 cells. The electron spin resonance (EPR) spin
trapping technique was used to examine free radical generation mediated
by NSC3852 and the source of its production. Our results indicated that
NADPH oxidase is responsible for NSC3852 mediated •O2- generation.
7.

NSC3852 induced an increased accumulation of •O2- in the cells,

thus we predicted that the GSH/GSSG ratio in the cells exposed to
NSC3852 should also be altered. Obtained data indicated that superoxide
formation induced by NSC3852 changed the redox status of the cells
(GSH/GSSG ratio).
8.

Based on the obtained results we proposed model of NSC3852

mechanism of action.
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II. MATERIALS AND METHODS

1. Materials

1.1. Cells

MCF-7 cells and MDA-231 cells were provided by Dr. Marc Lippman (Lombardi
Cancer Center, Georgetown University). MCF-10A cells were obtained from American
Type Culture Collection.

1.2.Chemicals

All National Service Center (NSC) compounds were kindly provided by Dr. Robert
Schultz (Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program,
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD).
Quinidine-HCl was purchased from Sigma Chemical Company (St. Louis, MO). NAcetyl-L-cysteine (A-7250) was obtained from Sigma.

1.3. Plasmids

The pE2F-TA-Luc, pMyc-TA-Luc and control plasmid, TA-Luc were purchased
from Clontech Laboratories, Inc. (Palo Alto, CA).
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1.4. Antibodies

The Rb (C-15, sc-50) antibody, which reacts with phosphorylated and nonphosphorylated forms of Rb p110 of mouse, rat and human origin was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-E2F-1 (# 05-379), clones KH20 &
KH95 (mixed mouse monoclonal IgG2a) with epitopes mapped to amino acids 1-89 and
342-386, respectively were purchased from Upstate Biotechnology (Lake Placid, NY).
E2F-2 (L-20, sc-632), E2F-3 (N-20, sc-879), E2F-4 (RK-13, sc-551), E2F-5 (E-19, sc999), p130 (C-20, sc-317), p107 (SD9, sc-250), HSP70 (K-20, sc-1060) were also
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The HDAC1 (PA1-860)
antibody was obtained from Affinity BioReagents (Golden, CO). The Ki-67 (MIB-1,
Ab-1) antibody was obtained from Oncogene Science (Cambridge, MA). A peroxidaseconjugated anti-goat IgG (sc-2020), goat anti-mouse IgG (sc-2005), goat anti-rabbit IgG
(sc-2004) were purchased form Santa Cruz Biotechnology (Santa Cruz, CA) and used as
secondary antibodies for Western blots. Biotinylated anti-mouse IgG (H+L) (BA-2000,
Vector Laboratories, Inc.) was used as the secondary antibody for Ki-67
immunohistochemistry.
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2. Methods
2.1. Tissue culture
MCF-7 cells (passage #35-50) and MDA-MB-231 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (BioWhittaker, Walkersville, MD)
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HyClone
laboratories, Inc, Logan, Utah) and 0.04mg/ml gentamicin in a humidified atmosphere of
93% air, 7.0 % CO2 at 37°C. Experiments were performed in DMEM supplemented with
5% FBS. Cells were passaged every 4-5 days at a 1:5 (MCF-7) or 1:10 (MDA-231) ratio.
MCF-10A, immortalized human mammary epithelial cells, (passage #9-20), were
maintained in Mammary Epithelial Cell Growth Medium (MEGM) (Bio Whittaker)
according to the directions from the supplier and passaged weekly at a 1:4 ratio. All the
cells were counted using a hemocytometer and cell viability was determined by trypan
blue exclusion (0.02% trypan blue).

2.2. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium) Assay.

The MTS metabolism was used as an index of cell viability. MCF-7, MCF-10A or
MDA-MB-231 cells were plated at 4000 (MCF-7), 4000 (MCF-10A), 500 (MDA-MB231) cells/well in a 96-well plate in 225 µl DMEM/5% FBS or MEGM (MCF-10A).
Cells were left to attach for 24 hours and drugs were added. After 24 hours of treatment,
the medium was removed by aspiration and 100 µl of fresh DMEM/5% FBS or MEGM +
20 µl Cell Titer 96 (Promega, Madison, WI) was added. Cells were incubated for 2 hours
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at 37°C. Conversion of MTS reagent to a colored formazan product was measured by an
increase in absorbance at 490 nm using a Spectra Max 340pc plate reader (Molecular
Devices, Sunnyvale, CA). Under our assay conditions the MTS metabolism assay was
linear for 3 hours.

2.3 Oil-Red O assay

Cells (2.5 x 105cells/35 mm2 dish) were plated on sterile glass cover slips in fresh
growth medium (DMEM/5%FBS +/- drugs). After the treatment, the cover slips were
transferred into 60 mm2 glass dishes and 3 ml of cell fixative solution (10%
formaldehyde and 2% calcium acetate in PBS (phosphate buffer saline: 137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4 x 7H2O, 1.4 mM KH2PO4, pH 7.3)) were added. The
fixative was removed by aspiration after 3 minutes and 3 ml of freshly made Oil-Red O
working solution (Oil-Red O stock solution (0.5 % Oil-Red O (Sigma) in 98%
Isopropanol) diluted in water in a 3:2 ratio) were added. After 10 minutes of staining,
cells were rinsed with water and counterstained with Mayer’s hematoxylin solution
(Fisher, Pittsburgh, PA) for 1 minute at room temperature. Cells were briefly dipped in
0.4 % NH4 OH, rinsed in distilled water, mounted with 50% glycerol solution (1:1
dilution of Glycerol and water), and then dried for 10 minutes. An Ortholux microscope
(Ernst Leitz Wetzlar, Germany) (40x objective) was used to obtain images.
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2.4 Ki-67 immunohistochemistry

Cells (2.5 x 106 cells/35 mm2 dish) were plated on sterile glass coverslips in 3 ml
of DMEM/5% FBS +/- drugs. At the end of the treatment (24 or 48 hours) the medium
was removed by aspiration. Cells were fixed on the cover slips (10 minute incubation on
ice) using - 20°C fixing solution (50% acetone/50% ethanol). All the remaining steps
were performed at room temperature. Cells were rinsed with working PBS (wPBS)
solution (1x PBS, 0.15% bovine serum albumin). In order to block endogenous
peroxidase activity, freshly made Blocking solution #1 (1:100 dilution of 30% H2O2 in
methanol) was added to the cells for 15 minute. Cells were rinsed with wPBS, and then
blocking solution #2 was added for 30 minutes to block non-specific binding of
antibodies. The blocking solution was removed and 500 µl of Ki-67 antibody (1:50
dilution in wPBS) was added. (Cells used for the negative control remained in the
blocking solution #2). After one hour incubation, cells were rinsed with wPBS for 5
minutes and a secondary antibody (biotinylated anti-mouse IgG, 1:125 dilution in wPBS)
was added for 30 minutes. The secondary antibody was removed by rinsing cells with
wPBS for 5 minutes and B/A solution (Biotin-Avidin solution) was added. B/A was
prepared 30 minutes prior to use by adding 1 drop of each Reagent A and B (PK-6100,
Peroxidase Vectastatin Elite ABC kit, Vector Laboratories, Inc.). After 30 minutes in B/A
solution, cells were rinsed with wPBS for 5 minute and a peroxidase substrate, DAB
(750118, Research Genetics, Inc.) was added for 10 minutes. After that, cells were rinsed
with wPBS and counterstained with Mayer’s hematoxylin (Sigma) for 1-2 minutes to
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visualize cell nuclei. Coverslips were subsequently dipped in 0.4 % NH4OH solution in
tap water, dipped in 60% and 90% ethanol, respectively, and finally mounted using
Permount (Fisher Scientific, Pittsburgh, PA). Ki67 negative cells were visualized by light
microscopy (40x objective, Ortholux microscope, Ernst Leitz, Wetzlar, Germany). Cells
were individually assigned with negative or positive staining, and the Ki67 negative
percentage of the cell population was determined by counting using Image-Pro Plus
software (Media Cybenetics, Silver Spring, MD). In each coverslip, at least 500 cells
were counted.

2.5. Cell Death ELISA (enzyme-linked immunosorbent assay)

The release of nucleosomal fragment into the cytoplasm during the early stages of
apoptosis was quantified using the cell Death Detection ELISAPLUS kit (Roche Molecular
Biochemicals, # 1 774 425). Briefly, MCF-7 and MDA-MB-231 cells (4 x 103) were
plated in triplicate into 96-well plates +/- drugs for 72 hours or 24 hours, respectively.
After the treatment, cells were centrifuged for 10 minutes at 1000 rpm and the
supernatant was removed by inversion of the plate. The attached cells were resuspended
in 200 µl of lysis buffer (30 minutes) and centrifuged at 1000 rpm for 10 minutes. Cell
cytoplasmic fractions from each well were assayed in duplicate for the presence of
nucleosomes according to the directions from the suppliers. Briefly a quantitative
sandwich-enzyme-immunoassay-principle is applied to nucleosome detection using
mouse monoclonal antibodies directed against DNA and histones, respectively. As a
measure of the ability of each compound to induce apoptosis in MCF-7 and MDA-MB-
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231 cells, the nucleosome-enrichment fraction was calculated as the ratio of the
absorbance (405 nm) of drug-treated cultures / solvent exposed cultures.

2.6. Histone Deacetylase (HDAC) Fluorescent Activity Assay

The HDAC Fluorescent Activity Assay (Drug Discovery kit cat # AK-500,
BIOMOL Research Laboratories, Inc. Plymouth Meeting, PA) was used to screen drugs
for the ability to directly inhibit HDAC activity. This assay system measures histone
deacetylase activity present in a commercial HeLa (human cervical cancer cell line) cell
nuclear extract, which is rich in predominantly HDAC1 and HDAC2 activity and was
used as the HDAC source. The HDAC substrate contains an acetylated lysine side chain.
After incubation with the HeLa nuclear extract, HDAC-mediated deacetylation of the
substrate sensitizes the substrate, and following addition of a developer agent, causes the
conversion of deacetylated lysine to a fluorophore. Briefly, reactions were performed at
room temperature in a 96-well microtiter plate. The potent HDAC inhibitor, trichostatin
A (35 nM), was used as a positive control. Diluted HeLa extract (15ul) +/- drugs were
added into appropriate wells. Diluted substrate (25ul) was added to each well and mixed
thoroughly; HDAC reactions were performed for 10 minutes. The developer (50ul) was
added into each well of the microtiter plate to stop the HDAC reactions. The plate was
incubated at room temperature for 10 minutes, and read in a microtiter-plate reading
fluorimeter (CytoFluor 4000, PerSeptive Biosystems, Inc., Farmingham, MA) using an
excitation at a wavelength in the range 350-380nm and emission in the range 440-460nm
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2.7. Western Blotting
Cells were plated (2x106/60 mm2) in 5ml DMEM / 5% FBS culture medium. Cells were
left to attach for 12 hours and drugs were added. After treatment, cell monolayers were
rinsed with PBS and harvested by scraping in 100°C Western lysis buffer (1% SDS,
10mM Tris, pH 7.4). Cell lysates were collected by syringe in 100-150µl, transferred into
1.5 ml tubes, passed through the syringe three times, to reduce viscosity and heated to
100°C for 5 minutes to inactivate proteases. Supernatant solutions were collected by
centrifugation in a microcentrifuge at 4°C for 5 minutes. Protein concentrations were
determined using the BCA assay (bicinchonic acid, Pierce, Rockford, IL). Following the
BCA assay, Dithiothreitol (DTT) and protease inhibitors were added to the final
concentrations indicated: DTT (1 mM), PMSF (phenylmethylsulfonyl fluoride, 1.0 mM),
aprotinin (1µg/ml), and leupeptin (1µg/ml). Protein samples containing 60-70 µg of
protein were diluted (4:1 ratio) in 5X Western sample buffer ( 0.3 M Tris-HCl, pH 7.0, at
ration 1:5 Glycerol, 3M SDS, 100 µl of saturated Bromophenol Blue solution, q.s. 10ml
with water; 12.5µl of 2-Mercaptoethanol/100µl was added to the 5X buffer, fresh each
time), incubated at 100°C for 3 minutes and then resolved on 10% acrylamide gels by
electrophoreses at 100V. Proteins were transferred to polyvinylidene difluoride
membranes (Invitrogen) at 25 V for 2 hours. Membranes were blocked at 4°C, overnight
in 3% non-fat powdered milk/Tris buffered saline (TBS: 0.02 M Tris-HCl, pH 7.5, 0.5 M
NaCl) + 0.05% Tween20 (TBST). Membrane were washed 3 times (5 minutes each
wash) with room temperature Western washing solution (0.1% non-fat dry milk, 0.1%
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chick ovalbumin, 1% FBS, 0.2% Tween20). After the washes, membranes were
incubated with primary antibody diluted in washing buffer for 3.5 hours (at room
temperature on a rocker). Following primary antibody hybridization, membranes were
washed 3 times, 5 minutes per each wash with Western washing solution followed by one
5-minute wash in TBST buffer. Membranes were hybridized with secondary antibody
diluted in TBST buffer for 40 minutes using the same conditions as for the primary
antibody. Membranes were washed 3 times (10 minutes each wash) with TBST. Signals
were visualized by incubating the membrane with a chemiluminescent peroxidase
substrate (Super Signal, Pierce, Rockford, IL) for 7 minute and exposing the membrane
to film (Eastman Kodak Co., Rochester, NY). Signals were quantified using FluorChem
(Alpha Innotech, San Leandro, CA) spot densitometry.

2.8. Immunoprecipitation (IP)
MCF-7 cells (3.5x106/100mm2) were plated in DMEM / 5% FBS culture medium.
Cells were left to attach for 12 hours and drugs were added. After 24 hours cells were
rinsed with ice-cold 1x PBS, harvested by scraping in pre-chilled Lysis Buffer (1% NP40, 0.02M Tris, pH 8.0, 0.135M NaCl, glycerol 1:10, 0.003M Sodium Vanadate) with
protease inhibitors (5µl of 200mM PMSF (phenylmethyl-sulfonyl fluoride) ,10µl
aprotinine, 2µl of 10mg/ml leupeptin/ml of NP-40 buffer) and transferred to 1.5ml
Eppendorf tubes. All the following steps were performed at 4°C. Samples were incubated
on ice for 10 minutes and then centrifuged for 20-30 minutes. The supernatant was
collected and transferred to clean tubes. Aliquots were removed for the determination of
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protein concentration by BSA assay. Protein A/G beads (20µ/l00-500 µg of protein) were
added and samples were rotated for 20 minutes at 4°C. Antibodies were added for
primary IP reaction and samples were rotated for three hour at 4°C. Protein A/G beads
(20µl/ 100-500µg of protein) were added for 1 hour. Samples were centrifuged and beads
were washed with NP-40 buffer. Western Blot Sample Buffer was added, samples were
heated to 100°C for 5 minutes to elute proteins and incubated on ice for 3minutes. After 2
minutes of centrifugation (to pellet the beads) immunoprecipitates were run on SDSPAGE and immunoblotted with antibodies. Protein signals were visualized by incubating
the membranes with a peroxidase substrate for 7 minutes to yield a chemiluminescent
product, detected by exposure of the membrane to Kodak X-OMAT film.

2.9. Reporter gene assay

Transient transfection procedure. All plasmids used in this assay were purified
using Qiagen DNA purification columns, according to the directions from the suppliers.
MCF-7 cells (2x106/60mm2 dish) were plated in 5ml DMEM / 5% FBS medium. After
45-48 hours, when cells reached about 90% confluency, cells were rinsed with 1xHBSS
(Hank’s Balanced Salt Solution) buffer and 2ml of Opti-MEM I medium (# 31985-070,
Invitrogen, Carlsbad, CA) were added, incubated for 40 minutes and then removed by
aspiration. Transfection mix was prepared by combining 100µl of mix A (OPTI-MEM I,
2.5µg plasmid DNA and Lipofectamine Plus (# 11514-015, Invitrogen) reagent) and 110
µl of mix B (OPTI MEM I and 4µl of Lipofectamine reagent (# 18324-020, Invitrogen);
mixes A and B were incubated separately for 20 minutes. Transfection was started by
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adding 200µl of transfection mix with 800µl of OPTI-MEM I to the cells. Transfection
was carried out for 5-6 hours and was terminated by exchanging the medium with freshly
made 5ml of DMEM / 5% FBS culture medium (without antibiotic) +/- drugs.
Luciferase Assay. After 24 hours post-transfection, cells were harvested by
scraping into ice-cold lysis buffer (25 mM Tris-phosphate, pH 7.8, 1% Triton X-100, 2
mM EDTA, 10% Glycerol). Cell lysates were transferred into 1.5ml Eppendorf
microcenrifuge and centrifuged at maximal speed (5 minutes, at 4°C). Aliquots (20 µl)
were removed for determination of protein concentration by BCA assay. Supernatant
solutions were transferred into clean tubes. Ice-cold luciferase sample buffer (25 mM
glycylglycyl, pH 7.8, 15mM MgSO4) (250 µl) were mixed with cell extracts (50 µl) in
12x75 mm polypropylene culture tubes. The samples were warmed to 25°C and
luciferase activity was measured using an Auto Luminat (LB 953, EG and G-Berthold)
equipped with a dual injection system. ATP solution (100 µl) (25 mM glycylglycyl, pH
7.8, 15 mM MgSO4, 20 mM ATP) and the luciferin solution (100µl) (25 mM
glycylglycyl, pH 7.8, 1 mM luciferin) were automatically injected into each sample and
the production of the light was measured. The same luminometer settings were used for
each experiment: incubation temperature =25°C, reading time =6 seconds, injection
amount =100µl. The relative light production obtained from 50 µl of cell extracts were
normalized to 200µg of cellular protein.
2.10. Comet Analysis
MCF-7 cells (2x105/35mm2 dish) were plated in 3 ml DMEM / 5% FBS culture medium.
Cells were left to attach for 12 hours and the drugs were added. After 24 hours, cells were
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rinsed with ice cold PBS, harvested and counted. Cells were pelleted in a 15 ml conical
tubes by centrifugation (Sorvall GLC-2B centrifuge, Hoffman Estates, IL) for 5 minutes
at 1200 rpm (Sorvall GLC-2B), washed with 1ml ice cold PBS, centrifuged again and
resuspended in ice cold PBS at (1x105 cells/ml). The PBS cell suspension (50µl) was
mixed with 500 µl of 42°C low melting point agarose, spread evenly (75µl) onto a Comet
Slide (# 4250-050-03, Trevigen, Gaithersburg, MD) and allowed to dry flat for 30
minutes at 4°C (protected from light). Slides were then immersed in prechilled lysis
solution (# 4250-050-01, Trevigen), incubated on ice for 45 minutes, and then transferred
to freshly prepared alkali solution (300 mM NaOH, 1 mM EDTA, pH 8.0) for 45 minutes
at room temperature (protected from light). Slides were aligned equidistant from the
electrodes of an electrophoresis apparatus and electrophoresed for 30 min at 1 V/cm and
300 mA. Slides were immersed in 70% ethanol for 5 min and then allowed to air dry
overnight at room temperature. Slides were stained with 50µl of SYBR Green stain (#
4250-050-05, Trevigen, Gathersburg, MD) for 7 minutes and five drops of filtered antifade solution (20mg p-phenylenediamine dihydrochloride tablet (Sigma # P7288), 2ml of
PBS, 18ml of glycerol) were added. The comets were visualized using a Nikon Eclipse
TS100 microscope with 63X objective and FITC (fluorescien isothiocyanate)-filter cube.
Comet images were captured and analyzed using the LAI Automated Comet Assay
Analysis System (Loats Associates, Inc. Westminster, MD). The tail moment [(%DNA)
(distance traveled)] was used for quantitative analysis of DNA damage for 80 comets per
treatment/experiment.
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2.11. Dihydroethidium Fluorescence
Cells (2.0 x 105cells/35 mm2 dish) were plated on sterile glass cover slips in fresh
growth medium (DMEM/5%FBS). Cells were left to attach for 12 hours and stimulated
with NSC3852. All subsequent steps were performed in the dark. The redox – sensitive
probe dihydroethidium was used to detect NSC3852 – stimulated superoxide generation.
Cytosolic dihydroethidium exhibits blue fluorescence (excitation at 335nm, emission
420nm), but once it is oxidized by superoxide to ethidium, it emits a bright red nuclear
fluorescence (excitation at 518, emission at 605). Dihydroethidium was dissolved in
DMSO (5µM) ( D-11347, Molecular Probes, Eugene, OR) then added to cell culture
medium for 15-30 minutes in incubator. Cell monolayer was washed three times with
cold PBS. Cells were then fixed with 10% formaldehyde for 10 minutes at room
temperature. Cells were washed with cold PBS and cover slips were mounted on slides
using five drops of anti-fade solution (20mg p-phenylenediamine dihydrochloride tablet
(Sigma # P7288), 2ml of PBS, 18ml of glycerol). Cells were visualized using a Zeiss
LSM 510 confocal microscope with 10x objective. Scale bars were generated and
inserted by LSM software.

2.12. Colorometric determination of reduced and oxidized glutathione

The GSH and GSSG concentrations in MCF-7 cells were measured using an
enzymatic method (GSH/GSSG-412 kit; OxisResearch, Portland, OR). Cells (3.0 x
106cells/60 mm2 dish) were plated in 5 ml DMEM/5%FBS, left to attach for 12 hours.
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After the treatment, cells were washed with ice cold PBS, harvested, pelleted in a 15 ml
conical tubes by centrifugation (Sorvall GLC-2Bcentrifuge, Hoffman Estates, IL) for 5
minutes at 1200 rpm and resuspended in 200 µl of ice cold PBS. GSSG and GSH samples
were prepared according to the directions from the suppliers. Briefly, samples were
prepared in 5% MPA (metaphosphoric acid (Sigma M-5043) with or without M2VP (1Methyl-2-vinyl-pyridium trifluoromethane sulfonate), GSH specific scavenger. Ellman’s
reagent (5’5-dithiobis-2-nitrobenzoic acid (DTNB)) was added to samples. DTNB reacts
with GSH and form spectrophosphometrically detectable product at 412 nm (Spectra
Max 340pc plate reader (Molecular Devices, Sunnyvale, CA)). GSSG was determined by
reduction of GSSG to GSH mediated by glutathione reductase (GR), which was then
determined by the reaction with Ellman’s reagent.

2.13. ESR (Electron Spin Resistance) measurements

ESR spin trapping was used to detect production of short-lived free radical
intermediates. This technique involves the addition-type reaction of a short-lived radical
with a paramagnetic compound (spin trap) to form a relatively long-lived free radical
product (spin adduct), which can then be studied using conventional ESR. The intensity
of the signal is used to measure the amount of short-lived radicals trapped, and the
hyperfine couplings of the spin adduct are generally characteristic of the original trapped
radicals. The spin trapping is the method of choice for detection and identification of free
radical generation due to its specificity and sensitivity. All ESR measurements were
conducted using a Bruker EMX spectrometer (Bruker Instruments Inc. Billerica, MA
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01821, USA) and a flat cell assembly. Hyperfine couplings were measured (to 0.1 G)
directly from magnetic field separation using potassium tetraperoxochromate (K3CrO8)
and 1,1-diphenyl-2-picrylhydrazyl (DPPH) as reference standards ( Janzen E. G., et al.,
1968). The relative radical concentration was estimated by multiplying half of the peak
height by (ÿHpp)2, where ÿH pp represents peak-to peak width. The Acquisit program
was used for data acquisitions and analyses.
MCF-7 cells (2.0 x 106cells/60 mm2 dish) were plated in 5 ml DMEM/5%FBS.
After 48 hours cells were washed with HBSS, harvested and counted. Cells were pelleted
in a 15 ml conical tubes by centrifugation (Sorvall GLC-2Bcentrifuge, Hoffman Estates,
IL) for 5 minutes at 1200 rpm, washed with 1ml ice cold PBS, centrifuged again and
resuspended in ice cold PBS at 2 x106 cells/ml. The radical production of the cells was
then measured in the presence of the spin trap 5.5-dimethyl-1-pyrroline-N-oxide (DMPO,
Aldrich Chemical, WI). Reactants (100 mM DMPO, PBS, cells +/- stimulant) were
mixed in test tubes in a total volume of 1.0 ml incubated at 37 °C and transferred to a flat
cell for ESR measurements.

2.14. Statistics
The Sigma plot software (SpSS Inc., Chicago, IL), version 5.0 and Prism
(GraphPad software, Inc., San Diego, CA), version 3.0. were used for statistical analysis.
One way analysis of variance (ANOVA) was followed by the Dunnett’s test for
comparison of multiple groups with control. Statistically significant differences (P<0.05)
were determined using Student’s t-test.
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III. RESULTS

Chapter 1. Screening of Quinoline ring - containing compounds
Previous results in our laboratory have shown that quinidine, a quinoline ringcontaining drug, causes cell cycle arrest in G1 phase, cell cycle exit, inhibition of HDAC
as well as stimulates cellular differentiation in MCF-7 breast tumor cells (Zhou, Q et al,
2000). We hypothesized that the quinoline aromatic ring systems contain a property that
can induce antiproliferative changes in the cell and thereby lead to the restoration of a
differentiated phenotype in breast cancer cells. Twenty three quinoline ring – containing
compounds were obtained from NSC Compound Library or Sigma (Figure 6). The
objective of the following set of experiments was to test whether other pharmacologically
active quinolines possess the ability to arrest cell cycle, induce cellular differentiation
with subsequent apoptosis and inhibit HDAC activity in breast tumor cell lines.

Results presented in Tables 1 and 2 are collaborative work of several members of our
laboratory, and presented together to give the full picture of screening conducted. The
results obtained by me are shown in bold.
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NSC 10010

NSC 3852

NSC 14050 (CHLOROQUINE)

NSC 69603

NSC 86371

NSC 305819

NSC 10004 (QUINIDINE)

NSC 86373

NSC 85700

NSC 5362 (QUININE)

NSC4375(HYDROXYCHLOROQUINE)

NSC 124637

NSC 85701

NSC 13453 (AMODIAQUIN)

NSC 146397

NSC 4239

NSC 4238

NSC 2039
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NSC 149765 (PRIMAQUINE)

NSC 86372

QUINOLINE

Figure 6. Chemical structures of quinoline ring – containing
compounds.
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1.1. Survival of breast tumor cells treated with quinoline ring – containing
compounds

To determine IC50 values for antiproliferative activity of test compounds, the effect of
NCI compounds on cell viability was measured. Cells were plated in 96 well dishes at the
following densities: MCF-7 (4000), MDA-231 (500) and MCF-10A (4000). Tetrazolium
dye mitochondrial metabolism (MTS) assays were performed as detailed in Materials and
Methods and concentration / response analysis curves were built. Test NSC compounds
caused a decrease in a survival of breast cancer cells (Table 1). Data in Table1 shows
MTS metabolism IC50 determined for MCF-7 and MDA-MB-231 breast cancer cell lines
under our experimental conditions and GI50 determined using sulforhodamine blue (SRB)
staining reported by the NSC. MTS IC50 values for MCF-10A normal human mammary
epithelial cells were determined only for Chloroquine, NSC 3852, 10010, 69603, 86371
and 305819, because these compounds showed statistically significant differentiation
activity, determined by Ki-67 immunohistochemical assay (see section 1.2.).
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Table 1. MTS IC50 values and GI50 values obtained from NCI database.

MCF-7, MDA-MB-231 and MCF-10A cells were plated at density 4.0x103, 5.0x102 and
4.0x103 cells per well in 96-well plates, respectively, in 225 µl of 5% FBS DMEM or
MEGM (MCF-10A). The cells were grown for 12 hours. The NCI compounds were
added at ten different concentrations into each well of the plate and incubated for 48
hours. Cell growth was measured using a MTS assay kit. Data are the mean of n=2 or 3
independent experiments performed in triplicate. The concentration of each agent that
inhibited cell growth by 50% (IC50) was determined in each case using nonlinear
regression analysis to fit inhibition data to the dose-response curve. GI50 is a growth
inhibition index reported by the NCI.
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Table 1

MCF-7
NSC #

Name

14050
4375
13453
10004
5362
157387
305789
149765

Chloroquine
Hydroxychloroquine
Amodiaquine
Quinine
Mefloquine
Halofantrine
Primaquine
Quinoline

2039
3852
Quinolinic Acid
69603
305819
124637
4239
10010
86371
86373
86372
85700
85701
4238

MTS IC50
(uM)
33
57
7
113
40
3
11
3
62
8
10
28
14
7
13
0.7
4
6
13
0.2
7
4
0.4

MDA-231
SRB GI50
(uM)
19
nd
nd
nd
60
nd
10
16
nd
2
2
nd
0.9
13
14
2
5.4
nd
nd
0.1
7
4
2

MCF-10A

MTS IC50
(uM)
10.8
56.6
6

SRB GI50
(uM)
16
nd
nd

173

100

20.7
>100
nd
7.5
2
1.4
0.9
3.9
34.4
1
1
1.1
12.9
0.1
nd
0.6
0.7

20.5
43.7
nd
3
6.4
nd
0.6
9.4
17
6
1.3
nd
nd
0.2
33.2
nd
0.9

MTS IC50
(uM)
>100

9.5
2.6
55.6

3.2
28.2
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1.2. Accumulation of cytoplasmic lipid droplets in MCF-7 cells caused by NSC
compounds
To determine whether growth inhibition by NSC compounds was associated with cell
differentiation we assessed cytoplasmic lipid droplets accumulation defined by Oil Red
O. Based on the knowledge that lipid droplets are found in the cytoplasm of normal
epithelium (Jing, Y. et al, 1996), and the induction of differentiation in human breast
cancer cells by heregulin (Xiao-Feng Le et al, 2000) and retinoic acid (Bacus. S et al,
1990) is accompanied by the accumulation of cytoplasmic lipid droplets, we decided to
use lipid droplet accumulation as a marker of differentiation.
The MCF-7 or MDA-MB-231 cells were plated at a density of 2 x 105/35 mm2 dish in
3 ml of DMEM/5%FBS medium. After forty eight hour treatment cells were fixed and
the Oil Red O staining of the cells was performed. As shown in Figure 7, drug treated
cells displayed well defined accumulation of cytoplasmic lipid droplets compared to
control, where no accumulation of lipid droplets was observed. The range between the
concentrations needed to induce lipid droplets formation is between 0.1X the MTSIC50 to
2X MTSIC50 (Table 2). Lipid droplet formation is observed during cellular differentiation,
thus we concluded that quinoline ring – containing compounds induce cellular
differentiation in MCF-7 and MDA-231 breast cancer cell lines.
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MCF-7

Solvent

NSC 3852

NSC10010

Figure 7. Visualization of cellular differentiation in MCF-7 cells using Oil Red O
Histochemistry: 2 x 105 MCF-7 cells were plated in DMEM / 5% FBS cultured medium.
Cells were grown for 12 hours and then treated with NSC 3852 (10.0 µM) and NSC
10010 (4.0 µM) for 48 hours. Forty eight hours later cells were fixed and the Oil Red O
staining of the cells was performed. Cells were counter-stained with Mayer’s
hematoxylin to visualize the cytoplasmic lipid droplets (red color) and the cell nuclei
(blue color). Arrows indicate lipid droplets in cytoplasm.

61

1.3. Effect of NSC compounds on Ki67 antigen in MCF-7 cells
Ki-67 is a nuclear antigen present exclusively in cycling cells (Gerdes et al.
1983). Ki-67 antigen is thus used as a marker of cell proliferation, as it can not be
detected in non-proliferating cells.
MCF-7 cells were treated with NSC compounds at IC50 values for 48 hr. Ki-67
immunohistochemical assay was performed as described in Materials and Methods.
Figure 8 represents control and drug treated MCF-7 cells after immunohistochemical
staining of Ki-67 antigen (brown color) and counter-staining with Mayer’s hematoxylin
(blue color). Brown cells are Ki-67 positive and represent cells in G1, S, G2 and M phases
of cell cycle. Blue cells are Ki-67 negative and represent the population of nonproliferating (G0) cells. Ki-67 index in MCF-7 cells was calculated (Table 2). Ki-67
index equals % Ki-67 negative cells in drug-treated / % Ki-67 negative cells in control
cells. The Ki-67 index in the control cells equals one. The larger the Ki-67 index, the
greater the proportion of G0 cells in the population. Our results indicate that NSC10010,
NSC3852, Chloroquine, NSC86371, NSC69603, NSC305819 compounds were able to
shift significantly proliferating MCF-7 cells into G0 phase after 48 hours of treatment.
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MCF-7

10uM

Solvent

NSC 3852

4uM

NSC 10010

Figure 8. Ki-67 immunohistochemistry staining: 2 x 105 MCF-7 cells were plated in
DMEM / 5% FBS culture medium. Cells were grown for 12 hours on the glass cover
slips and then treated with NSC 3852 (10.0µM) and NSC 10010 (4.0µM). Forty eight
hours later cells were assayed for Ki-67 immunoreactivity. A minimum of 500 cells were
counted per slide. Brown staining indicates Ki-67 positive or cycling cells. Blue staining
indicates Ki-67 negative or G0 cells.
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1.4. Inhibition of HDAC enzymatic activity
Histone deacetylases are responsible for the hydrolytic removal of acetyl groups
from specific histone lysine residues, acetylation of which is catalyzed by histone
acetyltransferases (M. Grunstein, 1997).

Histone deacetylase inhibitors have shown

promise as anti-tumor agents (David M. Vigushin and R. Charles Coombers, 2002). This
has stimulated interest in the screening of compounds for HDAC inhibition (Gloria H. Su
et al, 2000).
We used a histone deacetylase in vitro assay to screen compounds for direct
HDAC inhibition activity. All the quinoline compounds were tested at their MTS IC50
levels. HeLa cells containing predominantly HDAC1 and HDAC2 were used as the
HDAC source. Data in Table 1 shows that only NSC86371 and NSC3852 directly
inhibited HDAC. All other quinoline ring – containing compounds, that induced a more
differentiated phenotype in MCF-7 human breast cancer cells failed to inhibit HDAC
activity. Thus, we concluded that HDAC inhibition is not required for the differentiation
response in MCF-7 cell treated by quinolines.

All following experiments were

conducted on NSC10010, NSC3852,

Chloroquine, NSC86371, NSC69603 and NSC305819 based on the fact that these
compounds showed significant differentiation activity in Ki67 assay.
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Table 2
Oil Red O: 2 x 105 MCF-7 or MDA-231 cells were plated in DMEM / 5% FBS cultured
medium. Cells were grown for 12 hours and then treated with serial dilutions of each
compound for 48 hr. Cells were fixed and stained with Oil Red O. Data represent the
lowest concentrations of each NSC compound that causes lipid droplet formation in
human breast cancer cell lines.
Ki-67 assay: MCF-7 cells were grown for 12 hours and then treated with MTS IC50
values of each compound for 48 hours. Immunohistochemistry of Ki-67 was performed.
Cells were visualized by light microscopy and individually assigned to Ki-67 positive and
Ki-67 negative groups. A minimum of 500 cells was counted per cover slip. The Ki-67
index equals % Ki-67 negative cells with drug treatment / % Ki67 negative cells in
control. The data are mean +/- SEM of three experiments.
HDAC activity: Direct inhibition of HDAC activity by test compounds was measured
using HDAC Fluorescence Activity Assay. MTS IC50 levels of each compound were
used.
* indicates significantly different from the control values (p<0.05).
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Table 2
Differentiation Activity

#

NSC #

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

14050
4375
13453
10004
5362
157387
305789
149765

Name
Chloroquine
Hydroxychloroquine
Amodiaquine
Quinine
Mefloquine
Halofantrine
Primaquine
Quinoline

2039
3852
Quinolinic Acid
69603
305819
124637
4239
10010
86371
86373
86372
85700
85701
4238

MCF-7

MDA-231

Oil Red
O
(uM)

Oil Red O
(uM)

1
5
10
10
30
Negative
5
2.5
Negative
15
10
Negative
1
1
1.3
3.5
1
1
2
1
0.5
0.7

27
15
8

0.8
2

5

1

MCF-7
Ki67 Index
6.6 *
3.6
2.4
5
4.1
0.3
1.4
1.1
0.4
1.6
7.2 *
0.4
6*
5.8 *
3.4
1.9
8.3*
6*
4.7
0.8
4.1
2.7
1.9

HDAC
activity
(%
control)
91 ± 1
86 ± 4
100 ± 13
102 ± 14
90 ± 2
81 ± 13
95 ± 14
96 ± 7
95 ± 4
69 ± 6 *
99 ± 6
111 ± 7
90 ± 17
127±14
96 ± 4
94 ± 8
65 ± 5 *
97 ± 2
91±7
97 ± 1
90 ± 7
109 ± 13
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1.5. NSC compounds cause growth suppression in MCF-7 breast cancer cells
Experiments were performed to assess the effects of NSC3852, 10010, 69603,
86371, 305819 and Chloroquine on MCF-7 cell growth.
MCF-7 cells MTS IC50 values of test compounds were used in this experiment.
Cell numbers were reduced by all test compounds (Figure 9). NSC10010 was the most
toxic compound; no surviving cells were detected in the dish after 72 hours of treatment.
NSC69603 had cytostatic effect on the cells. The data also demonstrate that only for
NSC305819 MTS IC50 concentration caused 50% decrease in cell number. This
observation suggests that growth inhibition is more sensitive indicator of toxicity than
MTS.

67

Figure 9. Growth suppression induced by NSC compounds:MCF-7 cells were plated
at the density 1.5 x 105 per 35mm dish. Cells were left to attach for 12 hours and MCF-7
cells MTS IC50 values of test compounds were added. Cells were harvested and counted
using hemocytometer at the times indicated. Data represent the mean ± S.M.E. range of 3
experiments. Arrow indicates the beginning of the treatment.
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1.6. Quinoline ring – containing compounds induce apoptosis in MCF-7 and MCF10A cells
There are two distinct forms of eukaryotic cell death: necrosis and apoptosis.
Apoptosis is the most common form of eukaryotic cell death (Katja C. Zimmermann and
Douglas R. Green, 2001). Inappropriate regulation of apoptosis plays an important role in
pathological conditions such as cancer (Gerard I. Evan and Karen H. Vousden, 2001).
During apoptosis the endogenous endonuclease cleaves double stranded DNA at the most
accessible internucleosomal linker regions, generating mono- and oligonucleosomes. Due
to the fact that DNA degradation occurs several hours before plasma membrane
breakdown, there is the specific stage of apoptosis that is characterized by the enrichment
of mono- and –oligonucleasomes in the cytoplasm of the apoptotic cells (Terui, Y. et al,
1995).
We used the cell death ELISA, based on a quantitative sandwich – enzyme –
immunoassay – principle to detect apoptosis in response to quinolines as described in
Materials and Methods. Mouse monoclonal antibodies directed against DNA and
histones, respectively allowed specific determination of mono- and oligonucleosomes in
the cytoplasmic fraction of cell lysates. Apoptosis measured as a nucleosome release is
reported here as the ratio of treated/control values. Nucleosome release values of the
control cells equal one. As shown in Figure 10, after 24 hours of treatment no
nucleosome release was detected in treated cells. After 48 hours cell treated with
NSC3852, NSC86371 and Chloroquine exhibit 4 times increase in nucleosome release
values compared to control. After 72 hours of treatment NSC3852, NSC305819,
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NSC86371 and Chloroquine exhibit 2.2, 2.7, 3.5 and 7.5 nucleosome release values
respectively.
No nucleosome release was detected in cells treated with NSC69603 and
NSC10010. Visual inspection of the dishes prior to the nucleosome assay showed that
cells treated with NSC10010 looked smaller, were not well attached and relative number
of the cells decreased compared to control cells. The nucleosome ELISA data for
NSC10010 can be explained by the fact, that stage of apoptosis that is characterized by
the enrichment of mono- and –oligonucleasomes in the cytoplasm of the apoptotic cells is
quite short and this stage of apoptosis might already be passed in the cells treated with
more toxic compounds by 24 hour time point. MCF-10A cells exposed to NSC69603 for
72 hours exhibit the highest (~5.5) nucleosome release values. The absence of the bar for
NSC10010 is explained by the absence of any survived cells after 48 hours of treatment
(Figure 10). NSC3852 had lower nucleosome release in MCF-10A than in MCF-7 cells.
Chloroquine did not cause any apoptosis in MCF-10A cells. NSC86371 and NSC305819
induced less apoptosis in MCF-10A cells compared to MCF-7 cells.
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Figure 10. Induction of apoptosis by NSC compounds: MCF-7 cell and MCF-10A
cells (4000 per well) were plated in 96-well plates. Twelve hours later test compounds
were added. In MCF-7 cells 24, 48 or 72 hours later and in MCF-10A cells 72 hours later
apoptosis was assayed using a nucleosome release ELISA. Apoptosis measured as a
nucleosome release is reported here as the ratio of treated/control values obtained in a
single experiment performed in triplicate. Statistically significant differences are
indicated (*P<0.05).
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1.7. DNA damage induced by quinoline ring compounds
Single gel electrophoresis assay (Comet assay) was used as an index of cytotoxic
effect of test compounds on MCF-7 cells. This method specifically evaluates DNA
damage in cells. The principle of the assay is based upon the ability of DNA fragments to
migrate out of the cells under the influence of an electric field. When a current is applied
undamaged DNA migrates slower, than DNA fragments (R. R. Tice et al, 2000).
Comet assay was performed to quantify DNA damage in MCF-7 and MCF-10A
cells. The greater the DNA damage, the longer the comet tail as quantified by tail
moment (Figure 11A), which measures the amount of damaged DNA in the tail and the
electrophoretic distance traveled.

Figure 11A shows that there is significant DNA

damage after 24 hours of treatment with NSC3852 compared to control. No statistically
significant damage to DNA by other compounds tested was detected. By 24 hours, few
cells were found in the dish treated with NSC10010, but DNA of those survived cells was
not damaged. Interestingly, no DNA damage was detected in MCF-10A normal human
mammary epithelial cells after 24 hour treatment with quinoline ring – containing
compounds, with the exception of NSC86371, where very little DNA damage occurred
(Figure 11C).
The data presented above suggest that NSC3852 selectively induced DNA
damage in MCF-7 breast cancer cells, but not in MCF-10A normal epithelial cells. Thus,
NSC 3852 not only caused a significant shift of cells into G0 phase of cell cycle it also
selectively induced DNA damage in MCF-7 breast cancer cells.
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Figure 11. DNA damage induced by quinolines
A. The example of three different samples of DNA with tail moment 0, 5 and 75
visualized by epifluorescence microscope. Cells were immobilized in a bed of low
melting point agarose, gently lysed and treated with alkali to unwind, denature the
DNA and hydrolyze sites of damage, following electrophoresis and staining of
samples with a fluorescent DNA intercalating dye. The distribution of DNA between
the tail and the head of the comet was used to evaluate the degree of DNA damage.
Tail Moment = [ (% DNA) (distance) ].
B. and C. MCF-7 and MCF-10A cells (1x105/35 mm2 dish) were treated with MTS
IC50 levels of the quinoline ring compounds for 24 hours. The number of comets with
tail moments ranging between 0-2, 5-10, 10-20, 20-50, 50-100 and >100 are plotted
for each treatment group. Eighty cells were analyzed per experiment. Data shown are
pooled results of the three independent experiments in each cell line. Statistically
significant differences are indicated (*P<0.05).
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Figure 11C. Comet assay

MCF-10A (24hr)
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1.8. NSC compounds cause growth suppression in MCF-10A normal mammary
epithelial cells
Very little DNA damage was detected in MCF-10A normal mammary epithelial cells
in response to treatment with NSC compounds. The next experiment was conducted to
evaluate the relative toxicity of these compounds in the MCF-7 breast cancer cell line
compared with MCF-10A normal human mammary epithelial cells. Therefore, we tested
whether the MCF-10A cell growth is inhibited at concentrations of compounds = MTS
IC50 in MCF-7 cells.
Short-term growth experiment showed that MCF-10A cell numbers were significantly
reduced by all of the test NSC compounds (Figure 12). Control MCF-10A cells increased
4 fold by 48 hours. NSC 305819 and Chloroquine inhibited increase in cell number.
MCF-10A IC50 values for these compounds were higher than MCF-7 IC50 values (Table
1), implying that these compounds are less toxic to MCF-10A compared to MCF-7.
NSC86371, 3852, 69603, 10010 reduced cell numbers below plating density. Compound
NSC10010 was clearly toxic to the cells after 48 hour treatment, which explains absence
of the bar for NSC10010.
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Figure 12. MCF-10A cell growth: MCF-10A cells were plated at a density 2 x 105 per
35mm2 dish. Cells were left to attach for 12 hours, then MCF-7 cells IC50 values of NSC
compounds were added. Forty eight hours later cells were harvested and counted. Data
represent the mean ± S.E.M. range of 3 experiments. The dashed line indicates the initial
number of cells plated at time zero.
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1.9. Significant findings and future directions
Twenty three quinoline ring-containing compounds were obtained from the NSC
Compound Library or Sigma. Test compounds examined in MTS assay were
antiproliferative in MCF-7 and MDA-231 breast cancer cell lines. IC50 values for
antiproliferative activity of test compounds were determined.
Next,

we

determined

whether

those

antiproliferatives

could

induce

cell

differentiation. Differentiation activity was measured by accumulation of lipid droplets
and the increase in Ki-67 index. The lowest concentration of compound that induced the
appearance of lipid droplets in MCF-7 and MDA-231 cell lines was determined and
compared to MTS determined IC50 values. The range between those concentrations was
between 0.1X MTSIC50 to 2X MTSIC50. All subsequent experiments were performed at a
single concentration, the MTSIC50. Ki-67 assay was performed, because it is more
definitive indicator of differentiation activity than Oil Red O assay. Ki-67 assay data
indicate that among all test compounds NSC10010, NSC3852, Chloroquine, NSC86371,
NSC69603, NSC305819 were able to significantly enrich the population of MCF-7 cells
in G0 phase after 48 hours of treatment.
Next, test compounds were screened in a cell-free assay for HDAC inhibitory
activity. Only NSC3852 and NSC 86371 significantly inhibited HDAC activity. Only
differentiation inducing quinolines (NSC10010, NSC3852, Chloroquine, NSC86371,
NSC69603, and NSC305819) were chosen for further screening.
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Cell growth experiments showed that NSC10010 was the most toxic in MCF-7 and
MCF-10A cells. Interestingly, DNA damage was not detected in live MCF-7 or MCF10A cells after 24 hours of treatment.
Chloroquine had cytostatic effect on MCF-7 cell growth by 48 hours, but by 72 hours
cell number went down, which correlates with finding that Chloroquine induced
apoptosis by 48 hours ~ 4.5 fold and by 72 hours ~7.5 fold. The delayed apoptosis effect
can explain the absence of DNA damage measured by Comet assay after 24 hours of
treatment. No DNA damage was detected in Chloroquine treated MCF-10A cells after 24
hours; Chloroquine exhibited cytostatic effect of MCF-10A after 48 hours of treatment.
NSC69603 suppressed MCF-7 cell growth at all time points. It did not cause either
apoptosis or DNA damage in MCF-7 cells by 24 hours. Apoptosis was not detected in
MCF-7 cells even by 72 hours, but it was significant in MCF-10A cells at that time point,
which might explain the cytotoxic effect NSC69603 had on MCF-10A cells after 48
hours of treatment. Comet assay preformed on MCF-10A cells did not show any DNA
damage after 24 hours of treatment.
NSC86371 had cytotoxic effect on MCF-7 by 24 hours. Induction of apoptosis in
MCF-7 cells by NSC86371 was significant and delayed (48 hours), subsequently no
DNA damage was detected in MCF-7 cells treated with NSC86371 for 24 hours.
NSC86371 induced apoptosis (72 hours), slightly induced DNA damage (24 hours), and
had cytotoxic effect (48 hours) on MCF-10A cells.
NSC305819 was the only compound that had cytostatic effect on MCF-7 cells. It
significantly induced apoptosis in MCF-7 cells by 72 hours, thus no DNA damage was
detected in these cells by 24 hours. NSC305819 had cytostatic effect on MCF-10 cell at
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48 hour time point. It induced apoptosis by 48 hours in MCF-10A cells, and did not cause
DNA damage in MCF-10A cells by 24 hours.
NSC3852 had cytostatic effects on MCF-7 cells in growth experiments. NSC3852
significantly induced apoptosis in MCF-7 by 48 hours, and NSC3852 selectively induced
DNA damage in MCF-7 cells by 24 hours (did not in MCF-10A cells). NSC3852 induced
apoptosis and had cytotoxic effect on MCF-10 cells by 48 hours.

Based on the reasons presented below NSC3852 has been chosen as a “lead”
compound for further investigation.
NSC3852 inhibited cell growth and induced differentiation (Ki-67 index) in MCF-7
cells. It was one of the two NSC compounds that significantly inhibited HDAC activity.
NSC3852 selectively induced DNA damage in MCF-7 cells by 24 hours (did not in
MCF-10A cells), and significantly induced apoptosis in MCF-7 by 48 hours. In the rapid
in vitro assay for transcellular permeation of drug through artificial lipid membrane
(PAMPA) NSC3852 was predicted to be active after oral administration (Martirosyan A.
R. et al., 2004). Furthermore, NSC3852 meets the Lipinski rule of five (a common set of
physicochemical properties frequently exhibited by drugs): a molecular weight ≤ 500, < 5
hydrogen-bond donors, < 10 hydrogen-bond acceptors, and an oil-water partition (log P)
between -1 and +5 (Lipinski C. A. et al., 1997).
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Chapter 2. NSC3852 modulate Rb/E2F-1/Myc pathway
The following experimental setting was used for all experiments discussed in
Chapter 2. MCF-7 cells were grown in T-75 tissue culture flask until 95-100%
confluency. At this point the cells are largely (~80%) in G0 /G1 phase (Wang L., et al.,
1998). This cell population was harvested and replated in tissue culture dish in
DMEM/5% FBS medium. Cells were left to attach for 12 hours, then solvent (0.001%
DMSO) or 10µM NSC3852 was added to the dishes. Cells were harvested in protein
harvesting buffer after the treatment.
Figure 13 shows temporal relationship between cell plating time, treatment time
and the MCF-7 cell cycle phase. All the data points discussed in the text refer to the hours
of treatment.
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Figure 13. Temporal relationship between cell plating time, treatment time and the
MCF-7 cell cycle phase.
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2.1. NSC3852 induces accumulation of hypophosphorylated pRb in MCF-7 cell.
The retinoblastoma tumor suppressor protein (pRb) is a cell cycle – regulated protein.
It is phosphorylated at specific points of G1 phase of the cell cycle. As a consequence of
its phosphorylation and dephosphorylation pattern, pRb acts as a switch for cell cycle
progression from G1 into S phase. Hypophosphorylated pRb represses cell cycle
progression by binding members of E2F family proteins and actively repressing
transcription from E2F responsive genes. At the G1 / S phase boundary, pRb becomes
hyperphosphorylated and loses its growth inhibitory function, permitting cell progression
into S phase (Tiziana Tonini et al, 2002). We hypothesized that NSC3852 cause cell
cycle arrest by inducing accumulation of hypophosphorylated pRb in breast cancer cells.
The purpose of this experiment was to test whether NSC compounds cause accumulation
of hypophosphorylated pRb and how rapidly pRb is shifted to its hypophosphorylated
form.
Figure 14 shows that by 6 hours in the control cells pRb was represented mostly by its
hyperphosphorylated form.

At 12 hours there is a shift of pRb from its

hypophosphorylated form to phosphorylated form. As expected, while cells were
progressing through the G1 phase of cell cycle, pRb in the control cells was in its
phosphorylated form (24hr.). Hypophosphorylated pRb appears again in the control cells
by 48 hours, when cells are in the S phase of the cell cycle (Figure 13). NSC3852
increased hypophosphorylated pRb levels in MCF-7 breast cancer cells compared to
control. Control levels of hypophosphorylated pRb at 6, 12, 24, 48 hour time point were
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set to 100%. Hypophosphorylated pRb levels in cells exposed to NSC3852 for 6, 12, 24
or 48 hours increased to 153%, 184%, 190% and 128% compared to control levels,
respectively.
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Figure 14. NSC3852 induced changes in pRb phosphorylation state
Synchronized MCF-7 cells were sub-cultured in DMEM/5% FBS. After 12 hour
incubation solvent control (C) or 10µM concentrations of NSC3852 (T) were added.
Cells were then harvested for Western blots at the times indicated. Data shown in the bar
graph are the mean hypophosphorylated pRb protein signals +/- S.E.M. of n = 1-3
experiments. Statistically significant differences in hypophosphorylated pRb level
(p<0.05) between control and drug treated cells are indicated by *.
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2.2. NSC3852 causes suppression of E2F-1 protein in MCF-7 cells
In the next experiment we tested the ability of NSC3852 to downregulate protein
levels of the E2F-1 transcription factor.
As shown in Figure 15, levels of E2F-1 protein in the control cells increased at the 12
and 24 hour time points. Upon the cell cycle progression (48 hour) E2F-1 levels in the
control decrease (lane 7). Immunoblot analysis demonstrated reduction in E2F-1 protein
levels after 12 hours (54% of the control) in the cells exposed to NSC3852 compared to
control (Figure 15). By 24 and 48 hours in NSC3852 levels of E2F-1 were reduced by
57% and 67% compared to control, respectively. This results support the hypothesis that
suppression of E2F-1 protein level is a mechanism that might contribute to cell growth
inhibition and differentiation caused by NSC3852, by preventing the induction of genes
necessary for cell cycle progression (c-myc, E2F-1, cdc25A, cyclin E, B-myb).
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Figure 15. Downregulation of E2F-1 protein level by NSC3852: Synchronized MCF-7
cells were sub-cultured in DMEM/5% FBS. After 12 hour incubation solvent, control (C)
or NSC3852 (T) at 10µM concentration was added. Cells were then harvested for
Western blots at the times indicated. Data shown in the bar graph are the mean E2F-1
protein signals +/- S.E.M. of n = 3 experiments. Control levels were set to 100% at each
time point. Statistically significant differences in E2F levels (p<0.05) between control
and NSC3852 treated cells are indicated by *.
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2.3. Immunoblot analysis of E2F protein family members
The E2F family is divided into three subgroups – transcriptional activators (E2F-1,
E2F-2 and E2F-3), transcriptional repressors (E2F4 and E2F-5), and a unique-acting
transcriptional repressor (E2F-6) (J. M. Trimarchi et al, 2001)). To assess the effect of
NSC3852 on different E2F family members in MCF-7 cells western blot analysis of E2F2, E2F-3, E2F-4, E2F-5 and E2F-6 was performed.
Figure 16 indicates that MCF-7 cells express all of the E2F family members. A 24 hour
exposure to NSC3852 did not change the protein levels of E2F-2, E2F-3, E2F-4 or E2F5. This finding suggests that among E2F family proteins, E2F-1 is a relatively selective
target of NSC3852.
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Figure 16. Effect of NSC compounds on E2F family members: MCF-7 cells were
plated at the density of 2 x 106 cells per 60 mm2 tissue culture dish in 5ml of DMEM/5%
FBS medium. Cells were left to attach for 12 hours. Solvent (DMSO) or 10µM NSC3852
were added to the dishes. Cells were harvested in protein harvesting buffer after 24 hour
incubation. Proteins levels were detected using chemiluminescent autoradiography and
quantitated using FluorChem (Alpha Innotech, San Leandro, CA) spot densitometry. n=1
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2.4. Accumulation of hypophosphorylated form of pRb induced by NSC3852 leads
to an increase in pRb/E2F-1 complex formation
The objective of this experiment was to test whether accumulation of
hypophosphorylated form of pRb induced by NSC3852 leads to the increase in pRb/E2F
complex formation in MCF-7 cells.
Immunoprecipitation of cell lysates was performed using E2F-1 antibodies, and
subsequent immunoblotting with pRb revealed E2F-1/ pRb complex. Control cells
(Figure 17) exhibited very low levels of E2F-1/pRb complex (lane1). pRb/E2F-1
complex formation increased more then two times after treatment with NSC3852. This
finding suggests that indeed there is an increase in pRb/E2F-1 complex formation in cells
treated with NSC 3852 regardless of the decrease of total E2F-1 protein levels in cells.
The results suggest that free E2F-1 in 3852 treated cells is very low.
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Figure 17. NSC compound increased pRb/E2F-1 complex formation: 3x106 MCF-7
cells were plated in DMEM / 5% FBS culture medium. After 12 hour incubation 10uM
NSC 3852 or solvent control were added to the cells for 40 hours. Cells were harvested
in harvesting buffer. IP was performed with whole cell extracts. Antibodies to E2F-1
were used for primary IP, and immunoprecipitates were then probed by immunoblotting
for pRb. n=2
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2.5. Suppression of Myc protein by NSC3852 in MCF-7 cells
Myc is a transcriptional target of E2F-1. Regulation of c-myc oncogene
expression plays an important role in control of cell proliferation and differentiation.
There are two E2F-1 consensus DNA – binding sites in the c-myc gene promoter
(Hiebert, S. W. et al., 1989). Furthermore, it has also been reported that overexpression of
Myc can simulate the expression of E2F-1 protein (Leone, G. et al., 1997). We
hypothesized that downregulation of free E2F-1 by NSC3852 and also increased E2F1/pRb complex might cause decreased Myc protein levels.
Figure 18 shows that Myc levels in the control cells increased between 12-48
hours (lane 1,3 and 5). Myc protein was downregulated by NSC compounds after 24 and
48 hours of treatment by ~ 50% and 60% respectively (Figure18). These results and
previous finding support our hypothesis that Myc protein, a downstream regulator of
E2F-1, may be downregulated as a result of suppression of E2F-1 levels and the increase
in E2F-1/pRb complex induced by NSC3852 .
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Figure 18. Downregulation of Myc protein level by NSC3852: Synchronized
MCF-7 cells were sub-cultured in DMEM/5% FBS. After 12 hour incubation, solvent
control or NSC3852 (10µM), respectively were added. Cells were then harvested for
Western blots at the times indicated. Data shown in the bar graph are the mean Myc
protein signals +/- S.E.M. of n = 3 experiments. Statistically significant differences in
Myc signal (p<0.05) between control and NSC3852 treated cells are indicated by *.
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2.6. NSC3852 influence on E2F-1 and Myc transcriptional activity
Our previous results showed that NSC3852 induced accumulation of
hypophosphorylated pRb, downregulated of E2F-1, increased E2F-1/pRb complex
formation and suppressed Myc protein levels. A transiently transfected reporter gene was
assayed to test whether transcriptional activity of E2F-1 and Myc proteins is
downregulated by NSC3852.
Results obtained from reporter gene assay are presented in Figure 19. Activation
of E2F-1 and Myc response elements was measured by assaying for the luciferase
reporter gene. Activity of E2F-1 and Myc response elements in the control cells was set
to 100%. Our results indicate that by 24 hours NSC3852 suppressed activity of E2F-1
and Myc response elements by 32% and 41%, respectively. These results are important,
because they demonstrate that, as we predicted, after 24 hours of treatment with
NSC3852 transcriptional activity of E2F-1 and Myc is significantly downregulated.
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Figure 19. NSC compounds affect E2F-1 and Myc transcriptional activity:
MCF-7 cells were transfected with 2.5ug/dish of E2F-TA-Luc and Myc-TA-Luc
plasmids. Transfection was terminated by aspirating medium and adding 5ml of the fresh
medium ± NSC 3852 (10uM) or solvent control. After 24 hours, cell extracts for
luciferase assay were prepared. Data shown in the bar graph are the mean +/- S.E.M. of n
= 3-5 experiments. Statistically significant differences (p<0.05) between control and
NSC3852 treated cells are indicated by *.
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2.7. Significant findings
NSC3852 was chosen as a lead compound for the further investigation. The purpose of
the experiments discussed in the second chapter was to test how NSC3852 regulates the
pRb/E2F-1/Myc pathway. In summary, our results show that NSC3852 induced
accumulation of hypophosphorylated pRb with the subsequent increase in E2F-1/pRb
complex formation in MCF-7 cells. NSC3852 selectively suppressed levels of E2F-1
protein among all the members of E2F family. Myc protein levels were also significantly
downregulated by NSC3852. A reporter gene assay was performed to test the effect of
NSC3852 on E2F-1 and Myc proteins transcriptional activity showed that after 24 hours
of treatment with NSC3852 transcriptional activity of E2F-1 and Myc is significantly
downregulated.
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Chapter 3. NSC 3852 affect redox status of MCF-7 human breast cancer cell
It has been found that the redox potential (Ec) of normal proliferating cells is
below that of cancer cells. Ec can be calculated from the ratio of GSH (glutathione) /
GSSG (glutathione disulfide). Furthermore, several studies reported that elevated redox
potential cause the accumulation of pRb in its hypophosphorylated form by preventing
the phosphorylation of pRb protein, which in turn does not release E2F-1 protein and
subsequently transcription factors necessary for the progression of the cell cycle are not
synthesized (A. Hoffman et al., 2001). We hypothesize that NSC3852 caused mild
oxidation of the breast cancer cells, and through this mechanism induces
hypophosphorylation of pRb, growth arrest and differentiation (Figure 20). To test this
hypothesis we tested whether N-acetylcysteine (NAC), a GSH precursor, could reverse
the activities of NSC3852. It has been shown that N-acetylcysteine restores pRb
phosphorylation caused by depletion of intracellular GSH (Yamauchi A. et al., 1997).
This information provides a rationale to test the effect of NAC on the cells treated with
NSC3852.
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Figure 20. Model: NSC3852 mechanism of action.
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3.1. Modulation of pRb/E2F-1/Myc pathway by NSC3852 can be blocked by
pretreatment of MCF-7 cells with NAC
Several studies reported that elevated redox potential caused the accumulation of pRb
in its hypophosphorylated form by preventing the phosphorylation of pRb protein, which
in turn does not release E2F-1 protein and subsequently transcription factors necessary
for the progression of the cell cycle are not synthesized (A. Hoffman et al., 2001).
Western blotting was used to test whether NAC blocks the effect of NSC3852 on pRb,
E2F-1 and Myc proteins. In these experiments NSC2039, a structural analog of NSC3852
lacking the nitrosyl moiety, was used as a negative control. NSC2039 is unable to cause
cell cycle arrest (Table 2) in MCF-7 cells.
Figure 21 shows that one hour pretreatment with NAC blocked accumulation of
hypophosphorylated pRb induced by 24 hour NSC3852 treatment. NAC also protected
E2F-1 and Myc protein from NSC3852 induced downregulation (Figure 21). These
results support the hypothesis that NSC3852 induced changes involve a NAC sensitive
redox pathway. As predicted, NSC2039 did not affect the pRb/E2F-1/Myc pathway.
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Figure 21. NAC reverses the effect of NSC3852 on Rb/E2F-1/Myc pathway:
Synchronized MCF-7 cells were plated in 60mm2 dishes in 5ml DMEM/5% FBS at
density 2 x 106 cells per dish. Twelve hours later cells were pretreated with NAC for 1
hour. NSC3852 (10µM) or NSC2039 (8µM) was added after the pretreatment, for 24
hours. Cells were then harvested for Western blots. Proteins were resolved on 10%
polyacrylamide gels (80µg of each sample) and probed with antibodies to pRb, E2F-1
and Myc. Data shown in the bar graph are the mean protein signals +/- S.E.M. of n =2-3
experiments. Statistically significant differences are indicated by *.
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3.2. Effect of NAC on Ki-67 index in NSC3852 treated cell
As our results indicated (section 1.3.), NSC3852 was able to significantly shift
proliferating MCF-7 cells into G0 phase after 48 hours of treatment. Based on the fact
that modulation of pRb/E2F-1/Myc pathway (major pathway, which regulates cell cycle
progression from G1 into S phase) by NSC3852 was reversed by NAC (Figure 21), we
predicted that NAC would block increase in proportion of G0 cells in the population of
MCF-7 cells treated with NSC3852. Ki-67 antigen was used previously as a marker of
cell proliferation, as it can not be detected in non proliferating cells.
Our results (Figure 22) indicate that control dishes contained 6% of Ki-67 negative cell.
NSC3852 induced a significant increase (37%) in Ki-67 negative cells after 48 hours of
treatment. NAC alone did not cause changes in Ki-67 negative cell. Dishes pretreated
with NAC for 1 hour and then treated with NSC3852 for 48 hours contained 17% of Ki67 negative cells. This data indicate that NAC partially blocked the NSC3852 induced
shift of proliferating cells into G0 phase.

108

Ki-67 negative cells
(% of total)

50
*

40
30

*

20
10
0
Control

3852

NAC

NAC+3852

Figure 22. Effect of NAC on Ki-67 index in NSC3852 treated cells: 2 x 105 MCF-7
cells were plated in DMEM / 5% FBS culture medium. Cells were grown for 12 hours,
pretreated with NAC (5mM) for 1 hour and then NSC3852 (10µM) was added. Forty
eight hours later cells were assayed for Ki-67 immunoreactivity. A minimum of 500 cells
were counted per slide. Data are the mean +/- S.E.M. of n=3 experiments. Statistically
significant differences are indicated by *.
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3.3. NAC protects MCF-7 cells from DNA damaging effect of NSC3852
To determine the time point at which DNA damage induced by NSC3852 is most
severe we assayed DNA damage every 24 hours for 5 days. Figure 23 demonstrates that
NSC3852 induced DNA damage was detectable at 12 hours, and peacked at 24 hours, at
subsequent time points DNA damage decreased and was not detectable by 96 hours
(Figure 23A). These results together with data shown in Figure 10 suggest that NSC3852
induced DNA damage precedes cell apoptosis.
Oxidative stress is known to cause DNA damage (Guetens G. et al.,2002). The thiol Nacetylcysteine is a precursor of intracellular cysteine and glutathione, and thus buffers
cells from alterations of the redox status, as well as oxidative DNA damage (De Flora S.
et al., 2001). To test our hypothesis that NAC can block NSC3852 induced DNA damage,
we pretreated MCF-7 cells with 5mM NAC for 1 hour. After the pretreatment, NSC3852
or NSC2039 (negative control) was added to the cells. The Comet assay was performed
24 hours later to quantify DNA damage in MCF-7 cells. NAC blocked the DNA
damaging effect of NSC3852 (Figure 23B). As predicted, NSC2039 did not induce DNA
damage in MCF-7 cells after 24 hours of treatment.
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Figure 23. NAC protects MCF-7 from DNA damage caused by NSC3852.
A) MCF-7 cells (1x105/35 mm2 dish) were treated with 10 µM NSC3852. DNA
damage induced by NSC3852 was assayed at times indicated. Data shown are pooled
results of two independent Comet experiments.
B) MCF-7 cells (1x105/35 mm2 dish) were treated with 10 µM NSC3852 or 8µM
NSC2039. Twenty four hours later cells were assayed for DNA damage. The number
of comets with tail moments in ranges between 0-2, 5-10, 10-20, 20-50, 50-100 and
>100 are plotted for each treatment group. Eighty cells were analyzed per experiment.
Data shown are pooled results of the three independent Comet experiments in MCF-7
cells. Statistically significant differences are indicated (*P<0.05)
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3.4. NSC3852 induced apoptosis is blocked by NAC
In the next set of experiments we used a cell death ELISA to test, whether NAC
protected NSC3852 treated cells from apoptosis.
Apoptosis measured as a nucleosome release is reported here as the ratio of
treated/control values. Nucleosome release values in control cells equal one. As shown in
Figure 24, after 24 hours of treatments with NSC3852 no apoptosis was detected in
MCF-7 cells. After 48 hours of treatment cells exposed to NSC3852 exhibited
nucleosome release values equal to ~3.5. Cells stimulated with NSC3852 for 72 hour
exhibited nucleosome release values equal to ~2. As we predicted, cells pretreated with
NAC were completely protected from NSC3852 induced apoptosis.
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Figure 24. NAC blocks NSC3852 induced apoptosis. MCF-7 cell (4000 per well) were
plated in 96-well plates. Twelve hours later test compounds were added. 24, 48 or 72
hours later apoptosis was assayed using a nucleosome release ELISA. Apoptosis
measured as a nucleosome release is reported here as the ratio of treated/control values
obtained in a single experiment performed in triplicate. Statistically significant
differences are indicated (*P<0.05).
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3.5. NAC partially blocks growth inhibition of MCF-7 cells induced by NSC3852
The goal of this experiment was to determine whether NAC would protect cells
from growth inhibition induced by NSC3852 and test the effect of NSC2039 on MCF-7
cell growth.
The results are shown in Figure 25. Cell numbers in the control cultures increased
more than 5-fold by day four, and 13-fold by day 7. Cell growth was inhibited by 19% in
the cells pretreated with NAC compared to control cells.
Initially, NSC2039 (compound structurally similar to NSC3852; it lacks nitroso
substitution) had no effect on cell number, but was clearly toxic to cells after 48 hours.
No surviving cells were detected in the dish after 6 days of treatment. It is worth
mentioning that NSC2039 did not damage DNA in MCF-7 cells (section 3.2) after 24
hours of treatment and it had no effect on Rb/E2F-1/Myc pathway (Figure 21). All those
characteristics suggest that NSC2039 has an effect distinctive action from NSC3852’s
effect on MCF-7 breast cancer cells.
As it is shown in Figure 25, NSC3852 suppressed growth of MCF-7 cells and this
effect was partially reversed by NAC.
This data suggests that NAC restored cell growth effect is accounted in part to the
cellular protection by NAC from NSC3852 induced apoptosis and cell cycle arrest
(Figure 22, 24). However, there is NAC independent mechanism that modulates cell
cycle and differentiation in cells treated with NSC3852 (Figure 29).
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Figure 25. Growth curves: MCF-7 cells were plated at density 2 x 105 per 35mm
dish. Cells were left to attach for 12 hours, and pretreated (where indicated) with
NAC (5mM) for 1 hour. After one hour of pretreatment, NSC3852 (10 µM) or
NSC2039 were added. Cells were harvested and counted using a hemocytometer at
the days indicated. Data represent the n = 2-5 experiments.
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3.6. NSC3852 mediates ROS generation in MCF-7 cells
Based on the fact that NSC3852 induced changes involve NAC responsive redox
pathway we hypothesized that NSC3852 mediates ROS generation in MCF-7 cells. The
electron spin resonance (ESR) spin trapping technique was used to examine free radical
generation mediated by NSC3852. Short-lived radicals react with a paramagnetic
compound (spin-trap), in this case DMPO (5,5-dimethyl-1-pyrroline-N-oxide), and form
a relatively long-lived product, the so-called spin adduct, which can be studied by ESR
(G. M. Rosen et al., 1985).
MCF-7 cells treated with NSC3852 displayed a 1:2:2:1 quarter signal (with aH=
aN= 14.9G , where aH and aN denote hyperfine splitting of the α - hydrogen and the
nitroxyl nitrogen, respectively), indicative of the DMPO-OH adduct, whereas MCF-7
cells treated with NSC2039 (negative control) did not generate such a signal (Figure 26A,
B).
To test whether the observed signal is attributed to •O2- trapping rather than to
•OH

derived from H2O2, SOD (superoxide dismutase) or catalase were added into the

reaction mixture containing cells and NSC3852. Catalase, a scavenger of H2O2, had no
effect on the observed signal, whereas SOD quenched the signal (Figure 26E, H). This
result showed that the observed signal was attributable to •O2- trapping.
There are two major cellular sources for production of •O2- : flavoprotein –
containing NADPH oxidase complex and mitochondrial electron transport chain. To
determine, which enzymes were involved in NSC3852 mediated formation of •O2-,
inhibitors of those enzymes were used. Rotenone (50µM) (mitochnodrial oxidase
inhibitor, did not reduce the 3852 generated ESR signal, whereas DPI (20µM)
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(diphenylene iodonium), a potent and highly selective flavoprotein inhibitor reduced the
ESR signal (Figure 26G, E). These results support the hypotheses that NADPH oxidase is
responsible for NSC3852 mediated •O2- generation.
Interestingly, pretreatment with NAC for one hour did not prevent quarter signal
formation induced by NSC3852 (Figure 26C). Based on the fact that NADPH oxidase
produces •O2- outside the cells, we think that •O2- formed by the cells upon treatment with
NSC3852 should enter cells, before it can be reduced by GSH or/and NAC (Figure 29).
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Figure 26. Generation of free radicals in NSC3852 treated MCF-7 cells. ESR
spectra of MCF-7 cells (treated as indicated for 5 minutes) were recorded with spin
trap DMPO in a 2 x 106 cell suspension in a phosphate buffer solution (pH 7.4). A)
NSC3852 (10µM). B) NSC2039 (8µM). C) Cells pretreated with NAC (5mM) for
one hour and treated with NSC3852 (10µM). D) NSC3852 (10µM) + DPI (20µM).
E) NSC3852 (10µM) + catalase (2000U/ml). G) NSC3852 (10µM) + rotenone
(50µM). H) NSC3852 + SOD (200U/ml). The ESR spectrometer settings were:
receiver gain, 6.32 x 104; time constant, 4 ms; modulation amplitude, 1.0 G; scan
time, 41 s; number of scans, 3; and magnetic field, 3480 ± 100 G.
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3.7. Superoxide visualization by Dihydroethidium
Intracellular •O2- was visualized using the cell-permeable dye dihydroethidium
(Ye J. et al., 1999), which when oxidized by •O2- emits red fluorescence (intact
dihydroethidium exhibits blue fluorescence), as detailed in Materials and Methods.
As shown in Figure 27, twenty four hours exposure of MCF-7 cells to NSC3852
increased accumulation of •O2- in the cells compared to control cells. Increased
accumulation of •O2- in the cells in response to NSC3852 stimulation supports our
hypothesis that NSC3852 causes oxidation in MCF-7 cells.
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Control (24hr)
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Figure 27. Visualization of superoxide inside the cells. Cells (2.0 x 105 cells/35
mm2 dish) were plated on sterile glass cover slips, left to attach for 12 hours and
stimulated with NSC3852 for 24 hours. Dihydroethidium (5µM) was added into the
cell culture for 15 minutes, and the staining was carried out at 37 ºC. Cells were
washed with PBS, fixed and mounted on slides using anti-fade solution. Cells were
visualized using a Zeiss LSM 510 confocal microscope.
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3.8. GSH/GSSG ratio in MCF-7 cells is altered by NSC3852
The major redox couple in mammalian cells is glutathione-glutathione disulfide.
Changes in GSH/GSSG ratio in the cells indicate changes in the redox status of the cells.
NSC3852 stimulated •O2- production in the cells (section 3.7.), thus we predicted that
GSH/GSSG ratio in the cells exposed to NSC3852 should reflect this oxidative response
activity.
The GSH/GSSG ratio was measured after 15, 60 and 360 minutes of NSC3852
stimulation (Figure 28). Our data indicates that the GSH/ GSSG ratio after the NSC3852
(15, 60 and 360 minute) stimulation, decreased 1.8, 2.5 and 1.25 fold respectively,
compared to control cells. This data indicates that superoxide formation induced by
NSC3852 shifts a cellular redox status to a more oxidized redox potential. Taken together
data presented in Chapter 3 supports our hypothesis that NSC3852 causes mild oxidation
of MCF-7 breast cancer cells, which leads to the elevation of redox potential of the cells
and this mechanism contributes to the growth arrest, differentiation and apoptosis
induced by NSC3852.
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Figure 28. GSH/GSSG ratio in MCF-7 cells treated with NSC3852. MCF-7 cells (3 x
106 cells/60 mm2 dish) were plated, left to attach for 12 hours and NSC3852 (10µM) was
added for the time indicated. After the treatment cells were washed, harvested and
GSH/GSSG was assayed as described in Materials and Methods.
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Figure 29. Model. Based on the results presented above we propose the following model
of NSC3852 mechanism of action.
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IV. Discussion

High – throughput screening assays allow rapid screening of large compound
libraries to identify the most specific and potent compounds “leads” against known
targets. (Hertzberg R., P. et al., 2000). The present study was aimed at identifying a
“lead” compound after the screening of quinoline ring-containing compounds obtained
from the National Cancer Institute Compound Library as HDAC inhibitors, and further
testing of the “lead” compound to identify additional targets.
Cancer cells are poorly differentiated. Thus, the development of therapy that
induces the conversion of cancer cells to the original differentiated state, and is better
tolerated by patients will be a major advance in the treatment of cancer. Trichostatin A, a
direct HDAC inhibitor, causes cell differentiation (Marks P. et al., 2000). Non-HDAC
mechanisms of differentiation also exist. The vitamin A derivative, all-trans retinoic acid
has been shown to induce differentiation in cancer cells and became the first choice drug
in the treatment of acute promyelocytic leukemia (Tobita T. et al., 1997; McBurney M. et
al., 1993). Generally, differentiation therapy for solid cancer is ineffective. Therefore,
preliminary results from our lab, which showed that quinidine, a quinoline ringcontaining drug, causes cell cycle arrest, cell cycle exit and stimulation of cellular
differentiation in MCF-7 breast tumor cells was a promising finding, which suggested
that quinidine like compounds might induce differentiation in breast cancer cells (Zhou
Q. et al., 2000).
In this study we used Ki-67 and Oil-Red-O assays as indicators of differentiation
activity of the screened quinoline ring-containing compounds. Six compounds (NSC
10010, 3852, Chloroquine, 69603, 305819 and 86371) out of 23 compounds screened by
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us were identified as differentiation inducing agents (Figure 7, 8; Table 2). Furthermore,
compounds NSC3852 and NSC86371 were identified as in vitro HDAC inhibitory
quinolines (Table 2) at concentrations (10µM and 6 µM respectively) that induced
differentiation in MCF-7 cells. HDAC is one of the well studied targets for differentiation
therapy (Vagushin D.M. et al., 2001). Agents that inhibit HDAC enzymatic activity, such
as trichostatin A, superoylanilide hydroxamic acid are able to induce differentiation in
transformed cells (Marks P. et al., 2000).Compound NSC2039 is structurally similar to
NSC3852, but it lacks nitroso substitution. Interestingly, it had no statistically significant
effect on either HDAC activity or Ki67 index.
Six “hits” established by the first round of screening were further screened to
select a “lead” compound. We chose the following criterion for further screening: effect
of the compounds on MCF-7 cell number. All the differentiation-inducing quinolines
caused growth inhibition, measured by viable cell number in growth curves in MCF-7
and MCF-10A cells (Figure 9, 12). Our results indicated that compound NSC305819 was
the least toxic of all the differentiation-inducing quinolines in MCF-10A normal human
mammary epithelial cells and further investigation is needed to establish whether it has
tumor selective activity. NSC3852 and NSC86371 were slightly less growth inhibitory in
MCF-10A than in MCF-7 cells. NSC69603 and NSC10010 were more toxic in MCF-10A
cells.
We chose the induction of apoptosis as a second criterion for screening.
Deregulation of apoptosis plays an important role in cancer. Induction of apoptosis by
NSC compounds in time course experiments was tested (Figure 10). After 48 hours of
treatment with NSC3852, 86371 and chloroquine apoptosis was detected. By 72 hours
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apoptosis was also detected in cells treated with NSC305819. NSC86371, NSC305819
and NSC3852 induced less apoptosis in MCF-10A cells compared to MCF-7 cells and
Chloroquine did not induce apoptosis in MCF-10A cells. These results indicate that
induction of apoptosis by NSC3852, 86371, 305819 and Chloroquine contributed to cell
death.
The comet assay was used to assay DNA damage in treated cells. After 24 hours
of treatment only NSC3852 significantly induced DNA damage in MCF-7 breast cancer
cells (Figure 11). DNA damage was not observed in MCF-10A normal epithelial cells
after stimulation with differentiation-inducing quinolines. These results suggest some
selective toxicity of NSC3852. Time – dependent induction of DNA damage by other
differentiation-inducing quinolines will help to determine presence of DNA damage
component in induction of apoptosis.
We chose NSC3852 as the “lead” compound because it : a) inhibited cell growth
and induced cell differentiation in MCF-7 cells, b) significantly inhibited HDAC activity,
c) selectively induced DNA damage in MCF-7 cells with subsequent apoptosis, d) in the
rapid in vitro assay of transcellular permeation of drug through artificial lipid membrane
(PAMPA) NSC3852 was predicted to be active after oral administration (Martirosyan
A.R. et al., 2004), e) meets the Lipinski rule of five: a molecular weight ≤ 500, < 5
hydrogen-bond donors, < 10 hydrogen-bond acceptors, and an oil-water partition (log P)
between -1 and +5 (Lipinski C.A. et al., 1997).
The lead compound NSC3852 exerts multiple effects on MCF-7 breast cancer
cells. NSC3852 induced the accumulation of a hypophosphorylated (active) form of pRb
(Figure 14) with expected increase in E2F-1/pRb complex formation in MCF-7 cells
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(Figure 17). E2F-1/pRb repressor complex might recruit other co-repressors (such as
HDAC) and bind to the promoter region of E2F-1 target genes inducing cell
differentiation (Brehm A. et al., 1998). A second mechanism upon which NSC3852
modulated pRb/E2F-1 pathway was suppression of E2F-1 protein level (Figure 15) and
its transcriptional activity (Figure 19), and downregulation of E2F-1 is a necessary precondition for cells to undergo differentiation (Wong C.F. et al., 2003). Furthermore,
levels (Figure 18) and transcriptional activity (Figure 19) of Myc transcription factor,
which plays a critical role in the control of cell proliferation (Kelly K. et al., 1984),
cellular differentiation (Griep A.E. et al., 1988), apoptosis (Zindy F. et al., 1998) and is a
downstream effector of E2F also was significantly downregulated by NSC3852. Further
investigation is necessary to determine the effect of NSC3852 on the promoter activity of
E2F-1 and Myc transcription factors and the routes of their degradation.
Several studies implicate the redox status of the cells in the regulation of pRb
function. Cichillitti L. et al. reported that elevated redox potential causes the
accumulation of pRb in its hypophosphorylated form by inducing protein phosphatase
2A-dependent dephosphoryaltion of pRb, which in turn does not release E2F-1 protein
(Cichillitti L. et al., 2003). Others demonstrated that N-acetylcysteine restores pRb
phosphorylation caused by depletion of intracellular GSH (glutathione) (Yamauchi A. et
al., 1997). Glutathione is the primary buffer of intracellular redox potential. To gain
further insight into the mechanism of NSC3852 induced pRb hypophosphorylation in
MCF-7 cells we tested the hypothesis that NSC3852 induces slight oxidative stress in
MCF-7 cells that can be compensated for by N-acetylcysteine (NAC), a glutathione
precursor.

Our

results

demonstrated

that

NAC

blocked

accumulation

of
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hypophosphorylated pRb. Furthermore, NAC also blocked E2F-1 and Myc protein
downregulation induced by NSC3852 (Figure 21). These data suggests that induction of
oxidative stress may be involved in the differentiation response to NSC3852.
Reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, are
an important determinant of cellular redox potential. When mammalian cells are exposed
to reactive oxygen species, redox potential of the cells rises. Certain ROS species cause
direct DNA damage. NSC3852 was the only differentiation – inducing quinoline that
caused DNA damage in MCF-7 cells after 24 hours of treatment, followed by apoptosis
after 48 hours of treatment. NAC blocked DNA damage and apoptosis induced by
NSC3852 (Figure 23, 24). This led us to the hypothesis that NSC3852 induces ROS
formation in MCF-7 cells.
To examine free radical generation mediated by NSC3852 the electron spin
resonance (EPR) spin trapping technique was used (Figure 26). Our results indicated that
NSC3852 induced •O2- generation in MCF-7 cells via NADPH oxidase system. NADPH
oxidase complex is now recognized as a primary source of ROS. NADPH oxidase
catalyses one-electron reduction of molecular oxygen, with electron supplied by NADPH.
Formed •O2- can be further reduced to hydrogen peroxide and formed ROS pass through
the cell membrane inside the cell. Superoxide was visualized in the cells using
immunofluorescence technique (Figure 27). Thus, formed superoxide might be
responsible for DNA damage as well as the changes in redox status of the cells. A good
estimate of redox status of the cell can be calculated from the ratio of glutathione
(GSH)/glutathione disulfide (GSSG). Results presented in Figure 28 indicated that
superoxide formation induced by NSC3852 shifted a cellular redox status to a more
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oxidized redox potential. The ability of NSC3852 to induce accumulation of
hypophosphorylated pRb and the shift of a cellular redox status to a more oxidized redox
potential upon NSC3852 stimulation agrees with the model proposed by Hoffman et al.,
which presents correlation between redox potential of the cells and pRb phosphorylation
state (Hoffman A. et al., 2001).
Based on the results presented in this study we propose the following model of
NSC3852 mechanism of action on MCF-7 breast cancer cells (Figure 29). NSC3852
induces generation of •O2- via NADPH oxidase complex. NADPH oxidase produces •O2outside the cells and we think that •O2- formed by the cells upon treatment with NSC3852
entered cells causing oxidative stress. Inside the cells •O2- is partially reduced by GHS.
The ratio of GSH/GSSG in the cells is changed leading to the shift in cellular redox status
to a more oxidized redox potential. This triggers the pRb/E2F-1/Myc pathway
modulation and cell differentiation observed upon NSC3852 treatment. Involvement of
oxidative stress in induction of differentiation induction is supported by the data
demonstrating the inability of NSC2039, quinoline ring compound with no differentiation
activity, to induce generation of •O2- in MCF-7 cells (Figure 26). An excess of •O2- (not
reduced by GSH) causes direct damage to DNA, which leads to subsequent apoptosis.
Determination of oxidative DNA damage (detection of 8-oxoguanine) will help to
determine whether the DNA damage induced by NSC3852 is the result of oxidative
injury (Ogawa Y. et al., 2003).
Interestingly, neither cell-growth inhibition (Figure 25) nor induction of cell
differentiation (Figure 22) observed upon stimulation of MCF-7 cells with NSC3852 was

130

fully blocked by NAC. The nature of the NAC-independent effects of NSC3852 in MCF7 cells and its role in growth inhibition remains to be elucidated.
In summary, induction of a more differentiated phenotype by quinoline-ring
containing compounds is an important finding, suggesting their potential role in
differentiation therapy. Our data showed that atniproliferative activity of NSC3852
differentiation-inducing quinoline ring-containing compound was in part the consequence
of NSC3852-induced oxidative stress in MCF-7, which is associated with DNA damage,
induction of cell differentiation and apoptosis. It worth mentioning, that newer
antimalarial arteminisins are oxidizing agents, and have recently shown promise as breast
cancer antiproliferative agents (Efferth T et al., 2002). NSC3852 has a relatively simple
chemical structure and is a “lead” compound for further development of anticancer drugs.
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